

# Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner,<sup>1</sup> Elihu Estey,<sup>2</sup> David Grimwade,<sup>3</sup> Sergio Amadori,<sup>4</sup> Frederick R. Appelbaum,<sup>2</sup> Thomas Büchner,<sup>5</sup> Hervé Dombret,<sup>6</sup> Benjamin L. Ebert,<sup>7</sup> Pierre Fenaux,<sup>8</sup> Richard A. Larson,<sup>9</sup> Ross L. Levine,<sup>10</sup> Francesco Lo-Coco,<sup>4</sup> Tomoki Naoe,<sup>11</sup> Dietger Niederwieser,<sup>12</sup> Gert J. Ossenkoppele,<sup>13</sup> Miguel Sanz,<sup>14</sup> Jorge Sierra,<sup>15</sup> Martin S. Tallman,<sup>10</sup> Hwei-Fang Tien,<sup>16</sup> Andrew H. Wei,<sup>17,18</sup> Bob Löwenberg,<sup>19</sup> and Clara D. Bloomfield<sup>20</sup>

<sup>1</sup>Department of Internal Medicine III, University of Ulm, Ulm, Germany; <sup>2</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>3</sup>Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; <sup>4</sup>Department of Biomedicine and Prevention, Università di Roma "Tor Vergata," Rome, Italy; <sup>5</sup>Department of Hematology/Oncology, University of Münster, Münster, Germany; <sup>6</sup>Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; <sup>7</sup>Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; <sup>8</sup>Service d'Hématologie, Hôpital Saint-Louis, Paris, France; <sup>9</sup>Department of Medicine, University of Chicago, Chicago, IL; <sup>10</sup>Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>11</sup>National Hospital Organization Nagoya Medical Center, Nagoya, Japan; <sup>12</sup>Department of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany; <sup>13</sup>Department of Haematology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; <sup>14</sup>Department of Hematology, University Hospital La Fe, University of Valencia, Valencia, Spain; <sup>15</sup>Hematology Department, Hospital de la Santa Creu i Sant Pau, Jose Carreras Leukemia Research Institute, Barcelona, Spain; <sup>16</sup>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; <sup>17</sup>Department of Clinical Hematology, The Alfred Hospital, Melbourne, Australia; <sup>18</sup>Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; <sup>19</sup>Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and <sup>20</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH

**The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for**

**example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated**

**evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease. (*Blood*. 2017; 129(4):424-447)**

## Introduction

In 2010, an international expert panel, on behalf of the European LeukemiaNet (ELN), published recommendations for diagnosis and management of acute myeloid leukemia (AML).<sup>1</sup> These recommendations have been widely adopted in general practice, within clinical trials, and by regulatory agencies. During recent years, considerable progress has been made in understanding disease pathogenesis, and in development of diagnostic assays and novel therapies.<sup>2</sup> This article provides updated recommendations that parallel the current update to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia.<sup>3,4</sup> For diagnosis and management of acute promyelocytic leukemia, readers are referred to the respective recommendations.<sup>5</sup>

## Methods

The panel included 22 international members with recognized clinical and research expertise in AML. The panel met 3 times. Literature searches, categorization of evidence, and arrival at consensus were done as previously.<sup>1</sup> Relevant abstracts presented at the 2013 to 2015 meetings of the American Society of Hematology, and the 2013 to 2016 meetings of the American Association for Cancer Research, the European Hematology

Association, and the American Society of Clinical Oncology were reviewed.

## WHO classification

The current update of the WHO classification provides few changes to the existing disease categories (Table 1). Most importantly, a new category "myeloid neoplasms with germ line predisposition" was added (Table 2).<sup>6</sup>

## AML with recurrent genetic abnormalities

The molecular basis of AML with *inv(3)(q21.3q26.2)* or *t(3;3)(q21.3;q26.2)* was revisited showing that repositioning of a *GATA2* enhancer element leads to overexpression of the *MECOM (EVII)* gene and to haploinsufficiency of *GATA2*.<sup>7,8</sup> A new provisional entity "AML with *BCR-ABL1*" was introduced to recognize that patients with this abnormality should receive therapy with a tyrosine kinase inhibitor. Distinction from blast phase of chronic myeloid leukemia may be difficult; preliminary data suggest that deletion of antigen receptor genes (immunoglobulin heavy chain and T-cell receptor),

**Table 1. Myeloid neoplasms with germ line predisposition, AML and related precursor neoplasms, and acute leukemias of ambiguous lineage (WHO 2016)**

Myeloid neoplasms with germ line predisposition (see Table 2)	
AML and related neoplasms	AML and related neoplasms (cont'd)
AML with recurrent genetic abnormalities	Acute myelomonocytic leukemia
AML with t(8;21)(q22;q22.1); <i>RUNX1-RUNX1T1</i>	Acute monoblastic/monocytic leukemia
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); <i>CBFB-MYH11</i>	Pure erythroid leukemia#
Acute promyelocytic leukemia with <i>PML-RARA*</i>	Acute megakaryoblastic leukemia
AML with t(9;11)(p21.3;q23.3); <i>MLLT3-KMT2A†</i>	Acute basophilic leukemia
AML with t(6;9)(p23;q34.1); <i>DEK-NUP214</i>	Acute panmyelosis with myelofibrosis
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <i>GATA2,MECOM(EV11)</i>	Myeloid sarcoma
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); <i>RBM15-MKL‡</i>	Myeloid proliferations related to Down syndrome
Provisional entity: AML with <i>BCR-ABL1</i>	Transient abnormal myelopoiesis
AML with mutated <i>NPM1§</i>	Myeloid leukemia associated with Down syndrome
AML with biallelic mutations of <i>CEBPA§</i>	Blastic plasmacytoid dendritic cell neoplasm
Provisional entity: AML with mutated <i>RUNX1</i>	<b>Acute leukemias of ambiguous lineage</b>
AML with myelodysplasia-related changes	Acute undifferentiated leukemia
Therapy-related myeloid neoplasms¶	MPAL with t(9;22)(q34.1;q11.2); <i>BCR-ABL1**</i>
AML, NOS	MPAL with t(v;11q23.3); <i>KMT2A</i> rearranged
AML with minimal differentiation	MPAL, B/myeloid, NOS
AML without maturation	MPAL, T/myeloid, NOS
AML with maturation	

For a diagnosis of AML, a marrow blast count of ≥20% is required, except for AML with the recurrent genetic abnormalities t(15;17), t(8;21), inv(16), or t(16;16). Adapted from Arber et al.<sup>3</sup>

MPAL, mixed phenotype acute leukemia; NK, natural killer.

\*Other recurring translocations involving *RARA* should be reported accordingly: for example, AML with t(11;17)(q23;q12); *ZBTB16-RARA*; AML with t(11;17)(q13;q12); *NUMA1-RARA*; AML with t(5;17)(q35;q12); *NPM1-RARA*; or AML with *STAT5B-RARA* (the latter having a normal chromosome 17 on conventional cytogenetic analysis).

†Other translocations involving *KMT2A (MLL)* should be reported accordingly: for example, AML with t(6;11)(q27;q23.3); *MLLT4-KMT2A*; AML with t(11;19)(q23.3;p13.3); *KMT2A-MLLT1*; AML with t(11;19)(q23.3;p13.1); *KMT2A-ELL*; AML with t(10;11)(p12;q23.3); *MLLT10-KMT2A*.

‡Rare leukemia most commonly occurring in infants.

§Diagnosis is made irrespective of the presence or absence of multilineage dysplasia.

||At least 20% (≥20%) blood or marrow blasts AND any of the following: previous history of MDS or MDS/MPN; myelodysplasia-related cytogenetic abnormality (see list below); multilineage dysplasia; AND absence of both prior cytotoxic therapy for unrelated disease and aforementioned recurring genetic abnormalities. Cytogenetic abnormalities sufficient to diagnose AML with myelodysplasia-related changes are: Complex karyotype (defined as 3 or more chromosomal abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with *BCR-ABL1*); Unbalanced abnormalities: -7 or del(7q); -5 or del(5q); i(17q) or t(17p); -13 or del(13q); del(11q); del(12p) or t(12p); idic(X)(q13); Balanced abnormalities: t(11;16)(q23.3;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); t(2;11)(p21;q23.3); t(5;12)(q32;p13.2); t(5;7)(q32;q11.2); t(5;17)(q32;p13.2); t(5;10)(q32;q21.2); t(3;5)(q25.3;q35.1).

¶Cases should be classified with the related genetic abnormality given in the diagnosis.

#The former subgroup of acute erythroid leukemia, erythroid/myeloid type (≥50% bone marrow erythroid precursors and ≥20% myeloblasts among nonerythroid cells) was removed; myeloblasts are now always counted as percentage of total marrow cells. The remaining subcategory AML, NOS, pure erythroid leukemia requires the presence of >80% immature erythroid precursors with ≥30% proerythroblasts.

\*\**BCR-ABL1*<sup>T</sup> leukemia may present as MPAL; treatment should include a tyrosine kinase inhibitor.

*IKZF1*, and/or *CDKN2A* may support a diagnosis of AML rather than chronic myeloid leukemia blast phase.<sup>9</sup> AML with mutated *NPM1* and AML with biallelic mutations of *CEBPA* have become full entities; the latter category was restricted to cases with biallelic mutations because recent studies have shown that only those cases define the entity and portend a favorable outcome.<sup>10-16</sup> Both entities now subsume cases with multilineage dysplasia because presence of dysplasia lacks prognostic significance.<sup>17-19</sup> Finally, a new provisional entity “AML with mutated *RUNX1*” (excluding cases with myelodysplasia-related changes) was added; it has been associated with distinct clinicopathologic features and inferior outcome.<sup>20-24</sup>

**AML with myelodysplasia-related changes**

Presence of multilineage dysplasia, preexisting myeloid disorder, and/or myelodysplasia-related cytogenetic changes remain diagnostic criteria for this disease category. Deletion 9q was removed from the list of myelodysplasia-related cytogenetic changes because, in addition to its association with t(8;21), it also frequently occurs in AML with *NPM1* and biallelic *CEBPA* mutations.<sup>16,25</sup>

**AML, not otherwise specified**

The former subgroup acute erythroid leukemia, erythroid/myeloid type (≥50% bone marrow erythroid precursors and ≥20% myeloblasts among nonerythroid cells) was removed; myeloblasts are now always counted as percentage of total marrow cells. The remaining subcategory AML, not otherwise specified (NOS), pure erythroid leukemia requires >80% immature erythroid precursors with ≥30% proerythroblasts. French-American-British (FAB) subclassification does not seem to provide prognostic information for “AML, NOS” cases if data on *NPM1* and *CEBPA* mutations are available.<sup>26</sup>

**Myeloid neoplasms with germ line predisposition (synonyms: familial myeloid neoplasms; familial myelodysplastic syndromes/acute leukemias)**

Inclusion of this new category reflects the increasing recognition that some cases of myeloid neoplasms, including myelodysplastic syndrome (MDS) and AML, arise in association with inherited or de novo germ line mutations (Table 2).<sup>6,27-30</sup> Recognition of familial cases requires that physicians take a thorough patient

**Table 2. WHO classification of myeloid neoplasms with germ line predisposition and guide for molecular genetic diagnostics**

WHO classification	
<b>Classification*</b>	
Myeloid neoplasms with germ line predisposition without a preexisting disorder or organ dysfunction	
AML with germ line <i>CEBPA</i> mutation	
Myeloid neoplasms with germ line <i>DDX41</i> mutation†	
Myeloid neoplasms with germ line predisposition and preexisting platelet disorders	
Myeloid neoplasms with germ line <i>RUNX1</i> mutation†	
Myeloid neoplasms with germ line <i>ANKRD26</i> mutation†	
Myeloid neoplasms with germ line <i>ETV6</i> mutation†	
Myeloid neoplasms with germ line predisposition and other organ dysfunction	
Myeloid neoplasms with germ line <i>GATA2</i> mutation	
Myeloid neoplasms associated with bone marrow failure syndromes	
Juvenile myelomonocytic leukemia associated with neurofibromatosis, Noonan syndrome, or Noonan syndrome-like disorders	
Myeloid neoplasms associated with Noonan syndrome	
Myeloid neoplasms associated with Down syndrome†	
<b>Guide for molecular genetic diagnostics‡</b>	
Myelodysplastic predisposition/acute leukemia predisposition syndromes	
<i>CEBPA</i> , <i>DDX41</i> , <i>RUNX1</i> , <i>ANKRD26</i> , <i>ETV6</i> , <i>GATA2</i> , <i>SRP72</i> , 14q32.2 genomic duplication ( <i>ATG2B/GSKIP</i> )	
Cancer predisposition syndromes§	
Li Fraumeni syndrome ( <i>TP53</i> )	
Germ line <i>BRCA1/BRCA2</i> mutations	
Bone marrow failure syndromes	
Dyskeratosis congenita ( <i>TERC</i> , <i>TERT</i> )	
Fanconi anemia	

Classification portion of table is adopted from Arber et al.<sup>3</sup>

\*Recognition of familial myeloid neoplasms requires that physicians take a thorough patient and family history to assess for typical signs and symptoms of known syndromes, including data on malignancies and previous bleeding episodes. See also Churpek and Godley<sup>27</sup> for how to identify, test, and counsel individuals and families suspected of having an inherited myeloid malignancy syndrome.

†Lymphoid neoplasms also reported.

‡Molecular genetic diagnostics are guided by a detailed patient and family history<sup>27</sup>; diagnostics should be performed in close collaboration with a genetic counselor; patients with a suspected heritable myeloid neoplasm, who test negative for known predisposition genes, should ideally be entered on a research study to facilitate new syndrome discovery.

§Mutations in genes associated with cancer predisposition genes such as *TP53* and *BRCA1/2* appear to be frequent in therapy-related myeloid neoplasms.<sup>256</sup>

and family history, including information on malignancies and previous bleeding episodes. Awareness of these cases is of clinical relevance because patients may need special clinical care.<sup>27</sup> Affected patients, including their families, should be offered genetic counseling with a counselor familiar with these disorders.

## Molecular landscape

The advent of high-throughput sequencing techniques has allowed new insights into the molecular basis of myeloid neoplasms.<sup>31-37</sup> Similar to most sporadic human malignancies, AML is a complex, dynamic disease, characterized by multiple somatically acquired driver mutations, coexisting competing clones, and disease evolution over time.

The Cancer Genome Atlas AML substudy profiled 200 clinically annotated cases of de novo AML by whole-genome ( $n = 50$ ) or whole-exome ( $n = 150$ ) sequencing, along with RNA and microRNA sequencing and DNA-methylation analysis.<sup>31</sup> Twenty-three genes were found to be commonly mutated, and another 237 were mutated in 2 or more cases, in nonrandom patterns of co-occurrence

and mutual exclusivity. Mutated genes were classified into 1 of 9 functional categories: transcription factor fusions, the *NPM1* gene, tumor suppressor genes, DNA methylation-related genes, signaling genes, chromatin-modifying genes, myeloid transcription factor genes, cohesin complex genes, and spliceosome complex genes.

The use of genetic data to inform disease classification and clinical practice is an active field of research. Recently, 1540 patients, intensively treated in prospective trials, were analyzed using targeted resequencing of 111 myeloid cancer genes, along with cytogenetic profiles.<sup>37</sup> Patterns of comutations segregated AML cases into 11 nonoverlapping classes, each with a distinct clinical phenotype and outcome. Beyond known disease classes, 3 additional, heterogeneous classes emerged: AML with mutations in chromatin and RNA-splicing regulators; AML with *TP53* mutations and/or chromosomal aneuploidies; and, provisionally, AML with *IDH2*<sup>R172</sup> mutations.

Mutant allele fractions can be used to infer the phylogenetic tree leading to development of overt leukemia. Clonal evolution studies in patients and patient-derived xenograft models indicate that mutations in genes involved in regulation of DNA modification and of chromatin state, most commonly *DNMT3A*, *TET2*, and *ASXL1*, are often present in preleukemic stem or progenitor cells and occur early in leukemogenesis.<sup>38-41</sup> Such mutations are present in ancestral cells capable of multilineage engraftment, may persist after therapy, lead to clonal expansion during remission, and cause recurrent disease.

Recent studies in large, population-based cohorts have identified recurrent mutations in epigenetic regulators (*DNMT3A*, *ASXL1*, *TET2*), and less frequently in splicing factor genes (*SF3B1*, *SRSF2*), to be associated with clonal hematopoietic expansion in elderly seemingly healthy subjects.<sup>42-46</sup> The term “clonal hematopoiesis of indeterminate potential”<sup>47</sup> has been proposed to describe this phenomenon which seems associated with increased risks of hematologic neoplasms. Preliminary data indicate that the rate of progression of clonal hematopoiesis of indeterminate potential to hematologic disease may be similar to the rate of progression of other premalignant states, such as monoclonal gammopathy of undetermined significance to multiple myeloma.

## Diagnostic procedures

### Morphology

At least 200 leukocytes on blood smears and 500 nucleated cells on spiculated marrow smears should be counted. A marrow or blood blast count of  $\geq 20\%$  is required, except for AML with  $t(15;17)$ ,  $t(8;21)$ ,  $inv(16)$ , or  $t(16;16)$ . Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. In AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes, but not abnormal monocytes, are counted as blast equivalents.

### Immunophenotyping

Table 3 provides a list of markers helpful for establishing the diagnosis of AML,<sup>48</sup> as well as specific lineage markers useful for defining mixed-phenotype acute leukemia.<sup>3,4</sup>

### Cytogenetics and molecular cytogenetics

Conventional cytogenetic analysis remains mandatory in the evaluation of suspected AML. Eight balanced translocations and inversions, and

**Table 3. Expression of cell-surface and cytoplasmic markers for the diagnosis of AML and MPAL**

Expression of cell-surface and cytoplasmic markers	
<b>Diagnosis of AML*</b>	
Precursors†	CD34, CD117, CD33, CD13, HLA-DR
Granulocytic markers‡	CD65, cytoplasmic MPO
Monocytic markers§	CD14, CD36, CD64
Megakaryocytic markers	CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa)
Erythroid markers	CD235a (glycophorin A), CD36
<b>Diagnosis of MPAL¶</b>	
Myeloid lineage	MPO (flow cytometry, immunohistochemistry, or cytochemistry) or monocytic differentiation (at least 2 of the following: nonspecific esterase cytochemistry, CD11c, CD14, CD64, lysozyme)
T-lineage	Strong# cytoplasmic CD3 (with antibodies to CD3 $\epsilon$ chain) or surface CD3
B-lineage**	Strong# CD19 with at least 1 of the following strongly expressed: cytoplasmic CD79a, cCD22, or CD10 or weak CD19 with at least 2 of the following strongly expressed: CD79a, cCD22, or CD10

MPO, myeloperoxidase. Other abbreviations are explained in Table 1.

\*The markers proposed in this table are according to European LeukemiaNet Work Package 10 recommendations.<sup>48</sup>

†CD38 and other markers such as CD123 or CD133 can be added to identify leukemic stem cells, but do not contribute to diagnosis.

‡Of note, cells engaged in granulocytic maturation will retain the expression of CD13 and CD33 at various fluorescence levels. Seeking for the expression of CD15 and CD11b can provide further information. CD16 is only present on normal mature granulocytes. The absence of MPO together with myeloid markers defines AML with minimal differentiation which is different from acute undifferentiated leukemia.

§Of note, cells engaged in monocytic differentiation will retain the expression of CD13 and CD33. Seeking the expression of CD64 and CD11b can provide additional information, notably for promonocytes.

||CD42 (glycoprotein 1b) can also be used.

¶The category MPAL includes leukemias with expression of antigens of >1 lineage. They can either contain distinct blast populations of different lineages, or 1 blast population with expression of antigens of different lineages on the same cells, or a combination. The proposal in this table includes the modifications brought in the current update of the WHO classification of hematopoietic tumors.<sup>3,4</sup>

#Strong defined as equal or brighter than the normal B or T cells in the sample.

\*\*Other markers can be used to confirm B-lineage involvement.

their variants, are included in the WHO category “AML with recurrent genetic abnormalities”.<sup>3,4</sup> Nine balanced rearrangements and multiple unbalanced abnormalities are sufficient to establish the WHO diagnosis of “AML with myelodysplasia-related changes” when  $\geq 20\%$  blood or marrow blasts are present (Table 1).

Other rare balanced rearrangements are recognized.<sup>49,50</sup> Although considered disease-initiating events, they do not formally define disease categories. They involve genes, for example, encoding epigenetic regulators (eg, *KMT2A* [*MLL*], *CREBBP*, *NSD1*) or components of the nuclear pore complex (*NUP98*, *NUP214*) (Figure 1). Some rearrangements are cytogenetically cryptic, such as t(5;11)(q35.2;p15.4); *NUP98-NSD1*, which occurs in  $\sim 1\%$  of AML in younger adults and predicts a poor prognosis.<sup>51-53</sup> Recent studies have highlighted the potential of novel sequencing technologies to discover additional AML-associated fusion genes.<sup>54-56</sup>

If cytogenetic analysis fails, fluorescence in situ hybridization is an option to detect gene rearrangements, such as *RUNX1-RUNX1T1*, *CBFB-MYH11*, *KMT2A* (*MLL*), and *MECOM* (*EVII*) gene fusions, or loss of chromosome 5q, 7q, or 17p material.

### Molecular genetic testing

Diagnostic workup should include screening for (a) mutations in *NPM1*, *CEBPA*, and *RUNX1* genes because they define disease

categories (provisionally for *RUNX1*); (b) mutations in *FLT3* (both for internal tandem duplications [ITDs] together with data on the mutant-to-wild-type allelic ratio,<sup>57-60</sup> and tyrosine kinase domain mutations at codons D835 and I836); activating mutations of *FLT3* are not only prognostic, but may beneficially be affected by tyrosine kinase inhibition<sup>61</sup>; and (c) mutations in *TP53* and *ASXL1* because they consistently have been associated with poor prognosis (Table 4).<sup>62-70</sup>

Molecular testing by reverse transcriptase–polymerase chain reaction (RT-PCR) for recurring rearrangements can be useful (Table 4).

Although only a few of the recently identified molecular markers inform current clinical practice, the list (from the previous paragraph) will likely be expanded with testing for single genes replaced by gene panel diagnostics, or diagnostic platforms that simultaneously test for gene mutations and gene rearrangements.<sup>55,56</sup>

If AML with germ line predisposition is suspected, molecular testing should be performed in a specialized laboratory using a dedicated gene panel that includes the currently known predisposing alleles (Table 2).<sup>71</sup>

### Biobanking

If possible, pretreatment leukemic marrow and blood should be stored within a biobank. Informed consent preferably should allow a broad array of correlative laboratory studies including analysis of germ line DNA. Pretreatment samples should include nucleic acid (DNA and RNA, stored at  $-80^{\circ}\text{C}$ ) and viable cells (stored at  $-196^{\circ}\text{C}$ ). Optimally, a plasma sample, a methanol/acetic acid-fixed cell pellet (from cytogenetic analysis), and frozen cell pellets from various time points during and after treatment (eg, at time of complete remission [CR], relapse, and for minimal residual disease [MRD] monitoring at defined time points during remission) should be obtained and stored under appropriate conditions.

Buccal swabs and sputum have been previously recommended for the analysis of germ line DNA; samples should preferably be obtained during remission to reduce the risk of contaminating DNA from leukemic cells. Skin fibroblasts may be the preferred tissue source. A skin biopsy can be performed using a punch biopsy or by taking a small biopsy at the site of skin incision during bone marrow aspiration or biopsy. When obtained at diagnosis, skin cells should be grown from the biopsy to avoid contamination of the specimen with leukemic cells; alternatively, the biopsy can be taken during remission without growing of fibroblasts. Other sources include finger nails and hair follicles, although the amount of DNA that can be extracted may be limited. Finally, bone marrow fibroblasts can be grown from viably frozen mononuclear cells.<sup>72</sup>


### Other diagnostic tests

Tests and procedures for a patient with AML are described in Table 4.

## Prognostic factors

### Pretreatment factors

Recent studies have explored the relative contribution of genetic and clinical variables to prediction of event-free survival (EFS) and overall survival (OS).<sup>36,37,73,74</sup> Genomic lesions account for about two-thirds of explained variation, with the other third contributed by demographic, clinical, and treatment variables. However, models incorporating all of



**Figure 1. Molecular classes of AML and concurrent gene mutations in adult patients up to the age of ~65 years.** Class definition is based on the study by Papaemmanuil et al.<sup>37</sup> For each AML class denoted in the pie chart, frequent co-occurring mutations are shown in the respective boxes. Data on the frequency of genetic lesions are compiled from the databases of the British Medical Research Council (MRC), the German-Austrian AML Study Group (AMLSG), and from selected studies.<sup>37,87,88,299</sup> <sup>a</sup> indicates cohesin genes including *RAD21* (~10%), *SMC1A* (~5%), and *SMC3* (~5%); <sup>b</sup>, *inv(16)(p13.1q22)* or *t(16;16)(p13.1;q22)*; *CBFB-MYH11*; <sup>c</sup>, *inv(3)(q21.3q26.2)* or *t(3;3)(q21.3;q26.2)*; *GATA2, MECOM(EV11)*; and <sup>d</sup>, *TP53* mutations are found in ~45%, and complex karyotypes in ~70% of this class. The structure of the pie chart is adapted from Grimwade et al,<sup>50</sup> generated by Adam Ivey (King's College London, London, United Kingdom).

these factors and aimed at predicting whether a patient with a given set of covariates will have a longer remission or life expectancy than another patient with a different set of covariates are correct in only 75% to 80% of cases. This emphasizes the need not only to identify other pretreatment prognostic factors but also to focus on posttreatment events, in particular the presence of MRD (see “Factors after diagnosis”).

**Patient-related factors.** Increasing age is independently associated with poorer outcomes. Performance status, general health, and specific comorbidities modulate the effect of age on tolerance of chemotherapy (see also “Current therapy” and “Older patients not considered candidates for intensive chemotherapy”), whereas specific age-related AML-associated genetic abnormalities increase the likelihood of resistance, as do previous MDS, chronic myelomonocytic leukemia, myeloproliferative neoplasm (MPN), or prior exposure to cytotoxic therapy for other disorders. Hence, age should not be the sole determinant of treatment decisions.

**AML-related genetic factors.** Genetic abnormalities are powerful prognostic factors.<sup>36,37,50,73,75,76</sup> Results from conventional cytogenetics and from *NPM1*, *FLT3*, and *CEBPA* mutational screening are currently being used in routine practice following 2010 ELN recommendations.<sup>1</sup>

Recent data have led to several changes in these recommendations (see “2017 ELN genetic risk stratification” and Table 5). *RUNX1* mutations although occurring with unfavorable features, such as older age, antecedent myeloid disorder, and concurrent gene mutations (eg, *SRSF2*, *ASXL1*), identify patients with poor prognosis.<sup>20-23,37,70,73</sup> Likewise, *ASXL1* mutations are more common in older patients and associated with inferior survival.<sup>36,37,62-65,69,70</sup> *TP53* mutations are associated with complex karyotype,

monosomal karyotype, and specific chromosomal aneuploidies (eg,  $-5/5q-$ ,  $-7/7q-$ ), and predict for very poor outcome.<sup>37,66-70,73</sup> *TP53* mutation and complex karyotype provide independent prognostic information, with the combination of both having the worst outcome.<sup>37</sup>

The prognostic impact of many markers is context-dependent with the effect of a given abnormality dependent on the presence/absence of another.<sup>37</sup> Simple examples of such gene-gene interactions are that a *NPM1* mutation conveys a “favorable” prognosis only in the absence of a *FLT3*-ITD (or *FLT3*-ITD with a low allelic ratio),<sup>57-59,77</sup> whereas mutations in both *ASXL1* and *RUNX1* confer a particularly poor prognosis.<sup>37,65</sup> Furthermore, tightly correlated clusters of mutated genes, that is, mutations in RNA splicing (*SRSF2*, *SF3B1*, *U2AF1*, *ZRSR2*), chromatin (*ASXL1*, *STAG2*, *BCOR*, *KMT2A*<sup>PTD</sup>, *EZH2*), or transcription (*RUNX1*) regulators are found in high-risk MDS, high-risk MPN as well as secondary AML, indicating gene signatures identify high-risk myeloid disorders that cross-conventional diagnostic boundaries.<sup>37,78-82</sup>

In core-binding factor (CBF) AML, in particular in AML with *t(8;21)*, the presence of *KIT* mutations, especially if higher mutant *KIT* levels are present, appear to be associated with poorer prognosis.<sup>83-87</sup> Nevertheless, presence of a *KIT* mutation should not assign a patient to a different genetic risk category; rather, patients should be monitored for MRD, whose absence abrogates the effect of *KIT*.<sup>85</sup> Although both types of CBF-AML are associated with mutations in signaling genes (*NRAS*, *KIT*, *NF1*, *FLT3*, *KRAS*), recent comprehensive mutation profiling studies have revealed a different spectrum of cooperating mutations (Figure 1).<sup>87,88</sup> AML with *RUNX1-RUNX1T1* is significantly enriched for mutations in chromatin-modifying genes (42%-44%),

**Table 4. Tests/procedures for a patient with AML**

For a patient with AML	
Tests to establish the diagnosis	Additional tests/procedures at diagnosis (cont'd)
Complete blood count and differential count	Analysis of comorbidities
Bone marrow aspirate	Biochemistry, coagulation tests, urine analysis**
Bone marrow trephine biopsy*	Serum pregnancy test††
Immunophenotyping	Information on oocyte and sperm cryopreservation‡‡
<b>Genetic analyses</b>	Eligibility assessment for allogeneic HCT (including HLA typing) <sup>a</sup>
Cytogenetics†	Hepatitis A, B, C; HIV-1 testing
Screening for gene mutations including‡	Chest radiograph, 12-lead electrocardiogram, and echocardiography or MUGA (on indication)
<i>NPM1, CEBPA, RUNX1, FLT3, TP53, ASXL1</i>	Lumbar puncture <sup>b</sup>
Screening for gene rearrangements§	Biobanking <sup>c</sup>
<i>PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BCR-ABL1</i> , other fusion genes (if available)	<b>Sensitive assessment of response by RT-qPCR or MFC<sup>d</sup></b>
<b>Additional tests/procedures at diagnosis</b>	RT-qPCR <sup>e,f</sup> for <i>NPM1</i> mutation, <i>CBFB-MYH11</i> , <i>RUNX1-RUNX1T1</i> , <i>BCR-ABL1</i> , other fusion genes (if available) <sup>g</sup>
Demographics and medical history	MFC <sup>f,g</sup>
Detailed family history¶	
Patient bleeding history#	
Performance status (ECOG/WHO score)	

CMV, cytomegalovirus; ECOG, Eastern Cooperative Oncology Group; MUGA, multigated acquisition.

\*In patients with a dry tap (*punctio sicca*).

†Results from cytogenetics should be obtained preferably within 5 to 7 days. At least 20 bone marrow metaphases are needed to define a normal karyotype, and recommended to describe an abnormal karyotype. Abnormal karyotypes may be diagnosed from blood specimens.

‡Results from *NPM1* and *FLT3* mutational screening should be available within 48 to 72 hours (at least in patients eligible for intensive chemotherapy), and results from additional molecular genetics within the first treatment cycle. Screening for gene mutations is an evolving field of research; screening for single genes may be replaced by gene panel diagnostics.

§Screening for gene rearrangements should be performed if rapid information is needed for recommendation of suitable therapy, if chromosome morphology is of poor quality, or if there is typical morphology but the suspected cytogenetic abnormality is not present.

||Including race or ethnicity, prior exposure to toxic agents, prior malignancy, therapy for prior malignancy, information on smoking.

¶Thorough family history needed to identify potential myeloid neoplasms with germ line predisposition.

#History of bleeding episodes may inform cases of myeloid neoplasms with germ line predisposition and preexisting platelet disorders.

\*\*Biochemistry: glucose, sodium, potassium, calcium, creatinine, aspartate amino transferase, alanine amino transferase, alkaline phosphatase, lactate dehydrogenase, bilirubin, urea, total protein, uric acid, total cholesterol, total triglycerides, creatinine phosphokinase. Coagulation tests: prothrombin time, international normalized ratio where indicated, activated partial thromboplastin time. Urine analysis: pH, glucose, erythrocytes, leukocytes, protein, nitrite.

††In women with childbearing potential.

‡‡Cryopreservation to be done in accordance with the wish of the patient.

<sup>a</sup>HLA typing and CMV testing should be performed in those patients eligible for allogeneic HCT.

<sup>b</sup>Required in patients with clinical symptoms suspicious of CNS involvement; patient should be evaluated by imaging study for intracranial bleeding, leptomeningeal disease, and mass lesion; lumbar puncture considered optional in other settings (eg, high white blood cell count).

<sup>c</sup>Pretreatment leukemic bone marrow and blood sample; for further optional storing, see "Biobanking."

<sup>d</sup>Sensitive assessment of response can be performed at early time points, for example, following induction and consolidation courses to assess remission status and determine kinetics of disease response, and sequentially beyond consolidation to detect impending morphologic relapse. No generally applicable time points can be defined because kinetics of MRD response differs by treatment given, marker analyzed, and method used.

<sup>e</sup>Monitoring of response by RT-qPCR recommended in clinical trials and clinical practice.

<sup>f</sup>Sensitivity of response assessment varies by method used, and by marker tested; test used and sensitivity of the assay should always be reported; analyses should be done in experienced laboratories (centralized diagnostics).

<sup>g</sup>Increasing evidence that response assessment by MFC qualitatively provides a better remission status than morphologic assessment and is of high prognostic impact.

including *ASXL2*, and for mutations in cohesin complex genes (18%-20%), whereas they are nearly absent in AML with *CBFB-MYH11*.<sup>87-89</sup>

Although a genetic marker may currently not be prognostic, its presence may provide a target for new therapies as with *IDH1*, *IDH2*, and *KMT2A (MLL)*.<sup>2</sup> Likewise, a recent study in primary human samples identified co-occurrence of biallelic *CEBPA* mutations and mutations in the granulocyte colony-stimulating factor receptor gene *CSF3R* (signaling through the JAK-STAT pathway) as uniformly responsive to JAK inhibitors.<sup>90</sup>

**Factors after diagnosis**

**Monitoring of MRD.** Two approaches can be used to detect MRD, that is, multiparameter flow cytometry (MFC) and molecular techniques, including real-time quantitative PCR (RT-qPCR), digital PCR, and next-generation sequencing-based technologies. Standardized RT-qPCR assays are now available to detect AML-associated genetic lesions (Table 4). Each methodology

differs in the proportion of patients to whom it can be applied and in its sensitivity to detect MRD.<sup>91,92</sup> It is expected that integrated evaluation of baseline factors and assessment of MRD will improve risk assessment and inform postremission therapy.<sup>91-93</sup>

MRD can be assessed (1) at early time points, for example, following induction and consolidation courses to assess remission status and determine kinetics of disease response, and (2) sequentially beyond consolidation to detect impending morphologic relapse. Remission status as assessed by MFC (which is informative in ~90% of AML patients) provides a more reliable predictor of outcome than conventional morphology-based CR assessment.<sup>92-99</sup> MFC can be used to assess "CR without MRD" (CR<sub>MRD-</sub>) (see "Response criteria and outcome measures" and Table 6). The depth of response assessed by MFC has been consistently shown to provide independent prognostic information and thus may inform risk stratification. Currently, analyses should be performed in experienced laboratories, until MFC techniques have been further standardized.

**Table 5. 2017 ELN risk stratification by genetics**

Risk category*	Genetic abnormality
Favorable	t(8;21)(q22;q22.1); <i>RUNX1-RUNX1T1</i> inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); <i>CBFB-MYH11</i> Mutated <i>NPM1</i> without <i>FLT3-ITD</i> or with <i>FLT3-ITD</i> <sup>low</sup> † Biallelic mutated <i>CEBPA</i>
Intermediate	Mutated <i>NPM1</i> and <i>FLT3-ITD</i> <sup>high</sup> ‡ Wild-type <i>NPM1</i> without <i>FLT3-ITD</i> or with <i>FLT3-ITD</i> <sup>low</sup> † (without adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); <i>MLL3-KMT2A</i> ‡ Cytogenetic abnormalities not classified as favorable or adverse
Adverse	t(6;9)(p23;q34.1); <i>DEK-NUP214</i> t(v;11q23.3); <i>KMT2A</i> rearranged t(9;22)(q34.1;q11.2); <i>BCR-ABL1</i> inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); <i>GATA2, MECOM(EVI1)</i> –5 or del(5q); –7; –17/abn(17p) Complex karyotype.§ monosomal karyotypell Wild-type <i>NPM1</i> and <i>FLT3-ITD</i> <sup>high</sup> ‡ Mutated <i>RUNX1</i> ¶ Mutated <i>ASXL1</i> ¶ Mutated <i>TP53</i> #

Frequencies, response rates, and outcome measures should be reported by risk category, and, if sufficient numbers are available, by specific genetic lesions indicated.

\*Prognostic impact of a marker is treatment-dependent and may change with new therapies.

†Low, low allelic ratio (<0.5); high, high allelic ratio (≥0.5); semiquantitative assessment of *FLT3-ITD* allelic ratio (using DNA fragment analysis) is determined as ratio of the area under the curve “*FLT3-ITD*” divided by area under the curve “*FLT3-wild type*”; recent studies indicate that AML with *NPM1* mutation and *FLT3-ITD* low allelic ratio may also have a more favorable prognosis and patients should not routinely be assigned to allogeneic HCT.<sup>57-59,77</sup>

‡The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.

§Three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with *BCR-ABL1*.

llDefined by the presence of 1 single monosomy (excluding loss of X or Y) in association with at least 1 additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).<sup>116</sup>

¶These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.

#*TP53* mutations are significantly associated with AML with complex and monosomal karyotype.<sup>37,66-69</sup>

In ~60% of younger adults, the leukemia cells are informative for a molecular marker that can be tracked by RNA-based RT-qPCR assays. Assay sensitivity depends upon the relative expression of the target in leukemic blasts compared with standard housekeeping genes (eg, *ABL1*) and varies according to the target, as well as between patients with the same target.<sup>91</sup> Assays for *MLL3-KMT2A* are typically associated with the lowest sensitivity (~1 in 10<sup>3</sup>) due to relatively low-level fusion gene expression,<sup>100</sup> whereas assays for *NPM1* mutations achieve sensitivities of up to 1 in 10<sup>6-7</sup> due to the high-level mutant allele expression.<sup>101-106</sup> Many studies have shown that kinetics of MRD response to frontline therapy differs by molecular marker analyzed.<sup>85,101-109</sup> For example, reduction in *RUNX1-RUNX1T1* is slower than in *NPM1* transcript levels. Importantly, MRD status has been found to be a better predictor of relapse risk than presence of cooperating mutations involving *KIT* and *FLT3-ITD* in CBF-AML,<sup>85</sup> or *FLT3-ITD*, *DNMT3A*, and *WT1* in *NPM1*-mutated AML.<sup>106</sup> These data support inclusion of molecular MRD assessment into routine care to help inform transplant decisions in first remission.

Sequential MRD-monitoring studies have shown that persistent high-level PCR positivity, or a rising level of leukemic transcripts after an initial molecular response, invariably predict relapse.<sup>91</sup> Whether the opportunity thus provided for early intervention to prevent overt

relapse will be useful is under investigation. Preemptive therapy may be particularly relevant with allogeneic hematopoietic cell transplantation (HCT) where MRD status may inform conditioning strategy, or post-HCT measures aiming to avoid frank relapse.

Molecular markers can now be identified in virtually all cases. This has opened the way to detection of MRD using next-generation sequencing or digital PCR.<sup>91</sup> Although currently investigational, studies have already shown that mutational assessment at early time points can distinguish patients at differing probability of relapse.<sup>110,111</sup> Studies are needed to define which mutations are reliable indicators of leukemic clones associated with clinical relapse from mutations that are associated with preleukemic clones (eg, *DNMT3A*, *IDH1/2*) poorly predictive of relapse, although persistent at high levels after chemotherapy and during remission.<sup>106,112,113</sup>

### 2017 ELN genetic risk stratification

The original intention of the ELN genetic categories was to standardize reporting of genetic abnormalities particularly for correlations with clinical characteristics and outcome. The distinction between the intermediate I and intermediate II categories was based on genetic characteristics, rather than on prognostic stratification. Although a subsequent study demonstrated longer OS in the intermediate I group than the intermediate II group, the 2 groups were prognostically indistinguishable in older patients, who constitute the majority of cases of AML.<sup>114</sup>

Given these findings, the panel decided to simplify the ELN system by using a 3-group classification (favorable, intermediate, adverse) rather than the previous 4-group system (Table 5). A few other changes have been made. Recent studies have shown that in AML with *NPM1* or biallelic *CEBPA* mutations, the presence of coexisting chromosomal abnormalities does not appear to modify the prognostic effect of the mutations<sup>16,25,115</sup>; prognosis may be more influenced by concurrent gene mutations.<sup>37</sup> Accordingly, and as in CBF-AML, the categorization of these cases is now based on the primary leukemia-defining genetic subsets irrespective of the karyotype. The higher relapse rate and poorer OS associated with *FLT3-ITD* largely depends on the ITD allelic ratio. Most recent studies suggest that patients with *NPM1* mutation and *FLT3-ITD* with a low (<0.5) allelic ratio (*FLT3-ITD*<sup>low</sup>) have a similar (favorable) outcome as patients with a *NPM1* mutation but no *FLT3-ITD*; thus, both groups are now considered favorable.<sup>57-60</sup> In contrast, AML with wild-type *NPM1* and *FLT3-ITD* with a high (≥0.5) allelic ratio (*FLT3-ITD*<sup>high</sup>) has a poor prognosis and is placed in the adverse-risk group,<sup>57</sup> although the panel acknowledges that the natural course of AML with *FLT3* mutation may change by use of *FLT3* inhibitors.

*RUNX1*, *ASXL1*, and *TP53* mutations (see “Pretreatment factors”), and monosomal karyotype<sup>116-120</sup> have also been added to the adverse-risk group in recognition of their independent association with adverse risk. Although numerous studies have dealt with mutations in other genes, for example, *DNMT3A*, *IDH1*, *IDH2*, or genes in the chromatin/spliceosome group other than *ASXL1* and *RUNX1*, the panel did not feel enough evidence has as yet accumulated to warrant their assignment to an ELN prognostic group.

### Response criteria and outcome measures

The panel proposes a few new response categories. Although recognizing these are arbitrarily defined, they reflect recent data and aim at harmonizing definitions used in different trials (Tables 6 and 7).



**Table 6. Response criteria in AML**

Category	Definition	Comment
<b>Response</b>		
CR without minimal residual disease (CR <sub>MRD-</sub> )	If studied pretreatment, CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC	Sensitivities vary by marker tested, and by method used; therefore, test used and sensitivity of the assay should be reported; analyses should be done in experienced laboratories (centralized diagnostics)
Complete remission (CR)	Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC $\geq 1.0 \times 10^9/L$ (1000/ $\mu$ L); platelet count $\geq 100 \times 10^9/L$ (100 000/ $\mu$ L)	MRD <sup>+</sup> or unknown
CR with incomplete hematologic recovery (CR <sub>i</sub> )	All CR criteria except for residual neutropenia (<1.0 $\times 10^9/L$ [1000/ $\mu$ L]) or thrombocytopenia (<100 $\times 10^9/L$ [100 000/ $\mu$ L])	
Morphologic leukemia-free state (MLFS)	Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required	Marrow should not merely be "aplastic"; at least 200 cells should be enumerated or cellularity should be at least 10%
Partial remission (PR)	All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%	Especially important in the context of phase 1-2 clinical trials
<b>Treatment failure</b>		
Primary refractory disease	No CR or CR <sub>i</sub> after 2 courses of intensive induction treatment; excluding patients with death in aplasia or death due to indeterminate cause	Regimens containing higher doses of cytarabine (see Table 8) are generally considered as the best option for patients not responding to a first cycle of 7+3; the likelihood of responding to such regimens is lower after failure of a first
Death in aplasia	Deaths occurring $\geq 7$ d following completion of initial treatment while cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 d of death, without evidence of persistent leukemia	
Death from indeterminate cause	Deaths occurring before completion of therapy, or <7 d following its completion; or deaths occurring $\geq 7$ d following completion of initial therapy with no blasts in the blood, but no bone marrow examination available	
<b>Response criteria for clinical trials only</b>		
Stable disease	Absence of CR <sub>MRD-</sub> , CR, CR <sub>i</sub> , PR, MLFS; and criteria for PD not met	Period of stable disease should last at least 3 mo
Progressive disease (PD)*,†	Evidence for an increase in bone marrow blast percentage and/or increase of absolute blast counts in the blood: <ul style="list-style-type: none"> <li>&gt;50% increase in marrow blasts over baseline (a minimum 15% point increase is required in cases with &lt;30% blasts at baseline; or persistent marrow blast percentage of &gt;70% over at least 3 mo; without at least a 100% improvement in ANC to an absolute level (&gt;0.5 <math>\times 10^9/L</math> [500/<math>\mu</math>L], and/or platelet count to &gt;50 <math>\times 10^9/L</math> [50 000/<math>\mu</math>L] nontransfused); or</li> <li>&gt;50% increase in peripheral blasts (WBC <math>\times</math> % blasts) to &gt;25 <math>\times 10^9/L</math> (&gt;25 000/<math>\mu</math>L) (in the absence of differentiation syndrome)†; or</li> <li>New extramedullary disease</li> </ul>	Category mainly applies for older patient given low-intensity or single-agent "targeted therapies" in clinical trials In general, at least 2 cycles of a novel agent should be administered Some protocols may require blast increase in 2 consecutive marrow assessments at least 4 wk apart; the date of progression should then be defined as of the first observation date Some protocols may allow transient addition of hydroxyurea to lower blast counts "Progressive disease" is usually accompanied by a decline in ANC and platelets and increased transfusion requirement and decline in performance status or increase in symptoms
<b>Relapse</b>		
Hematologic relapse (after CR <sub>MRD-</sub> , CR, CR <sub>i</sub> )	Bone marrow blasts $\geq 5\%$ ; or reappearance of blasts in the blood; or development of extramedullary disease	
Molecular relapse (after CR <sub>MRD-</sub> )	If studied pretreatment, reoccurrence of MRD as assessed by RT-qPCR or by MFC	Test applied, sensitivity of the assay, and cutoff values used must be reported; analyses should be done in experienced laboratories (centralized diagnostics)

ANC, absolute neutrophil count; IDH, isocitrate dehydrogenase; MLFS, morphologic leukemia-free state; WBC, white blood cell.

\*The authors acknowledge that this new provisional category is arbitrarily defined; the category aims at harmonizing the various definitions used in different clinical trials.

†Certain targeted therapies, for example, those inhibiting mutant IDH proteins, may cause a differentiation syndrome, that is, a transient increase in the percentage of bone marrow blasts and an absolute increase in blood blasts; in the setting of therapy with such compounds, an increase in blasts may not necessarily indicate PD.



### CR<sub>MRD</sub>-

The category CR<sub>MRD</sub>- is proposed because relapse is more likely in patients in CR or CR with incomplete hematologic recovery (CRi) with detectable residual disease.<sup>91,92</sup> The best time to test for MRD in patients in CR by conventional criteria is not settled. Assessment of MRD after cycle 2 or even cycle 1 of induction allows earlier identification of poor responders.<sup>91,92,97,106</sup> However, MRD can disappear after consolidation therapy. The frequency with which this occurs may differ in different molecular subsets and future assessment of these frequencies will likely inform therapeutic decisions.

### Primary refractory AML

The panel proposes criteria for “primary refractory disease” (also commonly termed “induction failure”) because the definition of refractory disease currently differs in clinical practice and clinical trials. Failure to attain CR following exposure to at least 2 courses of intensive induction therapy defines patients to be “primary refractory.” Although possibly influenced by selection bias, CR rates from a second course of 7+3 can be 40% to 45%, which is often higher than the rate targeted by newer therapies.<sup>121</sup> Regimens containing higher doses of cytarabine are generally considered as the best option for patients not responding to a first cycle of 7+3. The likelihood of CR with a second course of a higher dose cytarabine-based regimen after failure of a first of the 2 cycles may be relatively lower than is the case with a second 7+3 after failure of a first.<sup>122,123</sup>

### Progressive disease

This proposed new category primarily applies to patients given less intense or single-agent targeted therapies. A uniformly accepted definition of progressive disease (PD) should facilitate a standardized interpretation of new drug trials. Because criteria for PD are arbitrary, it is unknown whether PD augurs a poorer prognosis than stable disease and warrants investigation. In the interim, observation of PD does not necessarily imply a patient should be removed from a given therapy.

## MDS-AML overlap/secondary AML

### Genetic basis

The related and partially overlapping clinical phenotypes of MDS and AML are reflected in the genetic bases of the 2 diseases.<sup>31,37,78-80,124</sup> A subset of mutations are highly specific for de novo AML, whereas another set of mutations is specific for secondary AML and are found commonly in MDS. Genetic analyses of a panel of genes mutated in myeloid malignancies, and perhaps the addition of gene expression and DNA-methylation profiling, have the potential to inform the distinction between MDS and AML, and to determine which cases of AML arose from an antecedent MDS.<sup>37,80,81</sup> The prognoses of patients with clinically diagnosed de novo AML whose gene mutation profile resembles those of patients with clinically diagnosed secondary AML is more like secondary than de novo AML.<sup>81</sup>

Mutations associated with secondary AML occur in genes encoding SRSF2, SF3B1, U2AF1, and ZRSR2 (splicing factors); ASXL1, EZH2, and BCOR (epigenetic regulators); and STAG2 (a member of the cohesin complex).<sup>81</sup> In such cases, these mutations likely occur during an MDS phase, remain in the clone that progresses to acute leukemia, and often persist in clonal remission following chemotherapy. Similarly, mutations in *ASXL1*, *EZH2*, and *SRSF2* genes have

been shown to identify patients with primary myelofibrosis who are at risk for leukemic transformation and who have particularly poor outcomes.<sup>82,125</sup> In contrast, *NPM1* mutations, and CBF and *KMT2A* rearrangements are highly specific for de novo AML.<sup>81</sup>

Genetic features in MDS that are associated with prognosis and progression to AML include mutations in *TP53*, *RUNX1*, *ETV6*, *EZH2*, and *ASXL1*.<sup>78-80,124,126</sup> *TP53* mutations are associated with a particularly poor survival, including following allogeneic HCT.<sup>127</sup>

### Blast count

Given the biologic overlap between secondary AML and MDS any minimum blast percentage used to distinguish AML from MDS with higher blast counts (ie, MDS with excess blasts-2 [MDS-EB2]) must be arbitrary. Thus, this minimum has decreased from 30% in the FAB system to 20% in the WHO system with many AML clinical trial groups allowing entry of patients with >10% blasts. Bone marrow failure is the usual cause of death in both AML and MDS-EB2, and most of the latter die without “progression to AML,” with data suggesting the natural history of MDS-EB2 is more similar to AML than to lower risk MDS.<sup>128,129</sup>

These observations suggest that it is best to determine eligibility for an “AML” or “MDS” study based on disease- and patient-specific factors rather than on a fixed blast percentage. Integration of data from molecular genetics into future classification systems will be useful to refine current diagnostic algorithms and support a more biologically precise disease classification.

## Current therapy

The general approach to current therapy has not changed substantially in recent years. Initial assessment evaluates whether a patient is considered a candidate for intensive induction chemotherapy. Although assessment of risk of treatment-related mortality (TRM) after intensive therapy is usually most relevant in older patients (commonly above the age of 65 years), age is merely one, and not the most important, predictor of TRM.<sup>130-135</sup> Furthermore, TRM rates are declining due to improved supportive care and to better health status in older patients.<sup>136,137</sup>

Therefore, age alone should not be the decisive determinant to guide therapy. Although few randomized trials have addressed the question and these trials have been small, there are suggestions that older, medically fit patients may benefit more from “intensive” than “nonintensive” induction therapy, subject to the constraints of selection bias.<sup>137</sup> Hence, although recognizing that firm criteria to consider older patients (or any patients) unfit for intensive induction therapy cannot be provided, the panel feels these should include only factors such as poor performance status and significant comorbidities and, in the case of conventional regimens such as 7+3, adverse ELN cytogenetics/molecular genetics (Table 5) because in these instances the benefit may not outweigh the risk. Results from cytogenetics should be obtained preferably within 5 to 7 days. Results from *NPM1* and *FLT3* mutational screening should be available within 48 to 72 hours (at least in patients eligible for intensive chemotherapy), and results from additional molecular genetics within the first treatment cycle. Abnormal renal or liver function should not be considered solely but in the context of other comorbidities and, although dose reduction may be called for, should not per se exclude patients from administration of intensive therapy. Several systems to quantify comorbidities and/or risk of TRM after intensive induction therapy have been proposed (see “Older patients not considered candidates for intensive chemotherapy”).

**Table 7. Outcome measures for clinical trials in AML**

Category	Definition
Overall survival	Defined for all patients of a trial; measured from the date of entry into a clinical trial or from the date of diagnosis (eg, for correlative science studies) to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive
Relapse-free survival (RFS)*,†	Defined only for patients achieving CR, or CR <sub>i</sub> ; measured from the date of achievement of a remission until the date of relapse or death from any cause; patients not known to have relapsed or died at last follow-up are censored on the date they were last examined
Event-free survival (EFS)†	Defined for all patients of a trial; measured from the date of entry into a study to the date of primary refractory disease, or relapse from CR, or CR <sub>i</sub> , or death from any cause; patients not known to have any of these events are censored on the date they were last examined
Cumulative incidence of relapse (CIR)†,‡	Defined for all patients achieving CR, CR <sub>i</sub> ; measured from the date of achievement of a remission until the date of relapse; patients not known to have relapsed are censored on the date they were last examined; patients who died without relapse are counted as a competing cause of failure

CID, cumulative incidence of death; CIR, cumulative incidence of relapse.

\*RFS and disease-free survival have been used with the same definition.

†In clinical trials in which the response criterion CR<sub>MRD-</sub> is used, consideration should be given to include molecular relapse as assessed by RT-qPCR or MFC as a criterion for relapse; similarly, for analysis of EFS, no achievement of CR<sub>MRD-</sub> may be regarded as an event. The definitions of RFS, EFS, and CIR must be clearly defined within each protocol.

‡It is important to provide estimates of CID as well because just considering the results of CIR may be misleading if, for instance, CIR is lower for 1 group but CID is actually higher for that same group.

### Intensive induction therapy

With 3 days of an anthracycline and 7 days of cytarabine (commonly referred to as “7+3” regimens), CR is achieved in 60% to 80% of younger adults and in 40% to 60% of older adults (60 years or above) (Table 8).<sup>1,2,138</sup>

**Anthracycline dose level.** Randomized studies have indicated that daunorubicin at 45 mg/m<sup>2</sup> daily ×3 is associated with a lower CR rate and a higher relapse rate than 90 mg/m<sup>2</sup> daily ×3 when daunorubicin is used in a single induction cycle.<sup>139-141</sup> This clear dose-effect relation seems much less prominent in patients >65 years of age. However, another comparison found that 90 mg/m<sup>2</sup> daunorubicin daily ×3 in a first induction cycle was not superior to daunorubicin at 60 mg/m<sup>2</sup> daily ×3.<sup>142</sup> In this study, both groups received additional daunorubicin at 50 mg/m<sup>2</sup> for 3 days once in CR which added significant toxicities to the high-dose schedule and may have obscured or counteracted the benefit of the 90 mg/m<sup>2</sup> during the first cycle. A recent exploratory analysis from this study suggests the potential for improved outcomes among patients with *FLT3*-ITD with anthracycline intensification, although this finding requires further validation.<sup>143</sup> Current evidence suggests that the dose of daunorubicin should not be <60 mg/m<sup>2</sup>.

In patients 50 to 70 years of age, daunorubicin (80 mg/m<sup>2</sup> for 3 days) or idarubicin (12 mg/m<sup>2</sup> for 4 days) were compared with the usual idarubicin schedule (12 mg/m<sup>2</sup> for 3 days). Although the CR rate was slightly higher with 4 days of idarubicin, there were no differences between the 3 arms in rates of relapse, EFS, or OS.<sup>144</sup>

**Cytarabine dose.** Recent studies<sup>123,145</sup> confirm earlier ones demonstrating increased toxicity without improvement in efficacy with higher dose cytarabine (2000-3000 mg/m<sup>2</sup>). A randomized trial found that fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor (G-CSF; FLAG) + idarubicin (FLAG-IDA) not only produced a lower relapse rate than daunorubicin-cytarabine with or without etoposide, but was also associated with more deaths in remission resulting in similar OS.<sup>123</sup> Only 1 randomized study has shown prolonged OS (52% vs 43% at 6 years) with cytarabine at 3000 mg/m<sup>2</sup> (every 12 hours, days 1, 3, 5, 7) compared with 100 mg/m<sup>2</sup> (daily ×7) in cycle I, but only in patients <46 and not 46 to 60 years of age.<sup>146</sup> The bulk of evidence indicates that cytarabine at doses >1000 mg/m<sup>2</sup> should not be included in induction regimens.<sup>147</sup> Furthermore, neither this study nor any others have shown that particular cytogenetic subsets benefit from such high cytarabine doses (see also “Conventional postremission therapy”).

**Role of other drugs. *FLT3* inhibitors.** The RATIFY trial evaluated intensive induction and consolidation chemotherapy plus midostaurin or placebo followed by a 1-year midostaurin/placebo maintenance phase in 717 patients aged 18 to 60 years with *FLT3*-mutated AML.<sup>61</sup> Use of midostaurin increased the CR rate when all CRs reported within 30 days of ending protocol therapy were considered (68% vs 59%; *P* = .04). The trial met its primary end point in improving OS (hazard ratio 0.78; *P* = .009), regardless of whether patients received allogeneic HCT. Thus, patients with *FLT3*-mutated AML may be considered to receive intensive chemotherapy in combination with midostaurin.

**Gemtuzumab ozogamicin.** The role of gemtuzumab ozogamicin (GO), an antibody-toxin (calicheamicin) conjugate that targets CD33<sup>+</sup> AML, is complicated. Two randomized studies using a single GO dose during chemotherapy in patients primarily age <60 years failed to show a survival advantage,<sup>148,149</sup> although the first used a suboptimal daunorubicin dose (45 mg/m<sup>2</sup>) in the GO arm vs 60 mg/m<sup>2</sup> in the control arm.<sup>148</sup> Both studies suggested the addition of GO was associated with longer relapse-free survival (RFS) in the favorable-risk subset of CBF-AML. The second study<sup>149</sup> extended this finding to survival in some patients with intermediate-risk cytogenetics. Two studies in older patients (median age, 61 and 67 years), 1 using a single 3 mg/m<sup>2</sup> GO dose and the other using 3 mg/m<sup>2</sup> GO on days 1, 4, and 7 of induction found survival benefit with GO, largely attributable to fewer relapses in patients with favorable- or intermediate-risk cytogenetics.<sup>150,151</sup> An individual patient data meta-analysis of these 4 studies and a fifth published in abstract form reinforced these conclusions.<sup>152</sup> In contrast, 1 large study in patients age 61 to 75 years found shorter survival (*P* = .071) in the GO arm largely reflecting higher early mortality in patients age 70 to 75 years.<sup>153</sup> The dose and schedule of GO may be critical for the benefit-toxicity ratio. GO is currently only available in clinical trials and through a compassionate use program sponsored by the US Food and Drug Administration (FDA).

**CPX-351.** CPX-351 is an encapsulation in nanoscale liposomes of cytarabine and daunorubicin at a synergistic 5:1 molar ratio.<sup>154-157</sup> Phase 2 studies suggested a beneficial effect of the agent in first-line treatment of secondary and therapy-related AML,<sup>155</sup> and in the poor-risk stratum (by the European Prognostic Index [EPI])<sup>158</sup> of relapsed AML.<sup>156</sup> A subsequent phase 3 trial randomized 309 patients age 60 to 75 years with high-risk AML, defined as AML with myelodysplasia-related changes or therapy-related AML, to CPX-351 or “7+3”.<sup>157</sup> CPX-351 produced a higher response rate (CR/CR<sub>i</sub>, 47.7% vs 33.3%; *P* = .016), and longer OS

**Table 8. Selected conventional care regimens for patients with AML**

Selected conventional care regimens	
<b>Patients eligible for intensive chemotherapy</b>	
Induction therapy (all ages) ("7+3"),†,‡	• 3 d of an IV anthracycline: daunorubicin at least 60 mg/m <sup>2</sup> ; idarubicin 12 mg/m <sup>2</sup> ; or mitoxantrone 12 mg/m <sup>2</sup> , and 7 d of continuous infusion cytarabine (100-200 mg/m <sup>2</sup> )
Consolidation therapy‡,§	
Younger patients (18-60/65 y)	
• Favorable-risk genetics	• 2-4 cycles of IDAC (1000-1500 mg/m <sup>2</sup> IV over 3 h q12h, d1-3; or 1000-1500 mg/m <sup>2</sup> IV over 3 h d1-5 or 6)
• Intermediate-risk genetics	• Allogeneic HCT from matched-related or unrelated donor
• Adverse-risk genetics	• 2-4 cycles of IDAC (1000-1500 mg/m <sup>2</sup> IV over 3 h q12h, d1-3; or 1000-1500 mg/m <sup>2</sup> IV over 3 h d1-5 or 6), or
Older patients (>60/65 y)	• High-dose therapy and autologous HCT
• Favorable-risk genetics	• Allogeneic HCT from matched-related or unrelated donor
• Intermediate/adverse-risk genetics	• 2-3 cycles of IDAC (500-1000 mg/m <sup>2</sup> IV over 3 h q12h, d1-3; or 500-1000 mg/m <sup>2</sup> IV over 3 h d1-5 or 6)
	• No established value of intensive consolidation therapy; consider allogeneic HCT in patients with low HCT-Comorbidity Index, or investigational therapy
<b>Patients considered not candidates for intensive chemotherapy  </b>	
Azacitidine¶	75 mg/m <sup>2</sup> , SC, d1-7, q4 wk, until progression
Decitabine#	20 mg/m <sup>2</sup> , IV, d1-5, q4 wk, until progression
Low-dose cytarabine**	Low-dose cytarabine (20 mg q12h, SC, d1-10, q4 wk; until progression); not recommended in patients with adverse-risk genetics
Best supportive care	Including hydroxyurea; for patients who cannot tolerate any antileukemic therapy, or who do not wish any therapy
<b>Common salvage regimens in patients not responding to a first induction cycle or with relapsed disease who are candidates for intensive therapy</b>	
IDAC†† (with or without anthracycline)	IDAC (1000-1500 mg/m <sup>2</sup> IV over 3 h q12 h, d1-3 [500-1000 mg/m <sup>2</sup> in patients >60 y]; or 1000-1500 mg/m <sup>2</sup> IV over 3 h d1-5 or 6 [500-1000 mg/m <sup>2</sup> in patients >60 y]); with or without daunorubicin 45-60 mg/m <sup>2</sup> , IV, d1-3; idarubicin 8-10 mg/m <sup>2</sup> , IV, d3-5, or mitoxantrone 8-10 mg/m <sup>2</sup> , IV, d1-3
FLAG-IDA‡‡	Fludarabine 30 mg/m <sup>2</sup> IV, d2-6; cytarabine 1500-2000 mg/m <sup>2</sup> IV over 3 h, starting 4 h after fludarabine infusion, d2-6; idarubicin 10 mg/m <sup>2</sup> IV, d2-4; G-CSF 5 µg/kg, SC, d1-5; additional G-CSF may be administered starting 7 d after end of chemotherapy until WBC count >500/uL Consider dose reduction in patients >60 y: fludarabine 20 mg/m <sup>2</sup> ; cytarabine 500-1000 mg/m <sup>2</sup> ; idarubicin 8 mg/m <sup>2</sup>
MEC	Mitoxantrone 8 mg/m <sup>2</sup> , d1-5; etoposide 100 mg/m <sup>2</sup> , d1-5; cytarabine 1000 mg/m <sup>2</sup> , d1-5
Allogeneic HCT	Consider transplantation for patients with primary refractory disease, for patients in second CR or with major cytoreduction but still active disease following salvage therapy Consider second transplantation under certain conditions (see "Salvage treatment") Perform early HLA typing

Patients should go on clinical trials if possible.

EMA, European Medicines Agency; FLAG-AMSA, FLAG + amsacrine; FLAG-MITO, FLAG + mitoxantrone; q, every; SC, subcutaneously.

\*Regimens containing higher doses of cytarabine are generally considered as the best option for patients not responding to a first cycle of "7+3" (see common salvage regimens).

†Older patients (in general >65 y) and patients with adverse genetics are less likely to respond to conventional induction therapy and may receive hypomethylating agents, or, preferably, investigational therapy.

‡Patients, at least those aged 18 to 60 y, with newly diagnosed AML and activating *FLT3* mutations may be considered to receive additional therapy with midostaurin (administered after the chemotherapy).<sup>61</sup>

§Results from assessment of MRD should be taken into account for selecting the appropriate consolidation therapy.

||For discussion of patients not considered candidates for intensive chemotherapy see first 2 paragraphs of "Current therapy."

¶Approved by FDA and EMA for adult patients who are not eligible for HCT with AML with 20% to 30% blasts and multilineage dysplasia; in addition, approved by EMA for patients who are not eligible for allogeneic HCT with AML with >30% marrow blasts.

#Approved by EMA (not by FDA) for patients with newly diagnosed de novo or secondary AML, who are not candidates for standard induction chemotherapy.

\*\*In some countries used in a dosage of 20 mg/m<sup>2</sup> SC once daily.

††Evidence from pharmacologic studies and clinical trials in first-line treatment indicate that doses higher than 1500 mg/m<sup>2</sup> are above the plateau of the maximal therapeutic effect;<sup>147</sup> single-agent IDAC should not be used in patients relapsing within 6 mo following consolidation with higher doses of cytarabine.

‡‡Idarubicin may be replaced by mitoxantrone 10 mg/m<sup>2</sup>, IV, days 2 to 4 (FLAG-MITO); or by amsacrine 100 mg/m<sup>2</sup>, days 2 to 4 (FLAG-AMSA).

(hazard ratio, 0.69; *P* = .005 with medians of 9.6 vs 6 months and 2-year survival rates of 31% and 12%). Results were similar after accounting for allogeneic HCT. Thus, CPX-351 may improve therapy of older patients with high-risk features.

**Purine analogs.** In 1 study, cladribine (at 5 mg/m<sup>2</sup> days 1-5) added to "7+3" in adults up to age 60 years produced a higher CR

rate and better OS than 7+3, particularly in patients age 50 to 60 years and in those with adverse-risk cytogenetics.<sup>159</sup> However, the relatively low CR rate (56%) and median OS (14 months) in the control arm have raised questions, and we await independent confirmation. In the intensive arm of their AML16 trial in older patients (median age, 67 years), the National Cancer Research

Institute (NCRI) Cooperative Group randomized 806 patients between daunorubicin (50 mg/m<sup>2</sup> days 1-3) and either cytarabine (100 mg/m<sup>2</sup> days 1-10) or clofarabine (20 mg/m<sup>2</sup> days 1-5). Rates of CR (66%-71%), relapse (68%-74% at 3 years) and OS (22%-23% at 3 years) were essentially identical.<sup>160</sup>

### Intensive postremission therapy

**Conventional postremission therapy.** Postremission strategies comprise intensive chemotherapy and high-dose therapy followed by autologous or allogeneic HCT (Table 8). Assessment of residual disease by RT-qPCR or MFC is critical in monitoring patients in morphological remission to inform further therapy (see “Factors after diagnosis”).

**Conventional intensive consolidation.** Consolidation regimens include single-agent cytarabine at high doses and multiagent chemotherapy which lead to similar outcomes. Administration of up to 4 cycles of high-dose cytarabine (2000-3000 mg/m<sup>2</sup>, commonly 6 doses per cycle) has been widely used. Recent trials have questioned the need for such high doses. One study randomized 933 patients, 15 to 60 years of age, between consolidation with mitoxantrone and cytarabine at 3000 mg/m<sup>2</sup> (every 12 hours for 6 days) vs a similar chemotherapy program, but with intermediate-dose cytarabine (IDAC) at 1000 mg/m<sup>2</sup> for consolidation with no differences in outcome.<sup>161</sup> Similarly, in a study with multiple randomizations in induction, the postremission comparison between cytarabine 3000 mg/m<sup>2</sup> and 1500 mg/m<sup>2</sup> (n = 657) showed no difference in survival.<sup>123</sup> A third study in 781 complete responders (15-64 years of age) failed to show a benefit for 3 cycles of cytarabine at 2000 mg/m<sup>2</sup> (every 12 hours for 5 days) compared with 4 cycles of a multiagent chemotherapy consolidation that contained 200 mg/m<sup>2</sup> cytarabine by 24-hour continuous infusion for 5 days.<sup>162</sup> None of these studies have identified a benefit of the high-dose cytarabine regimens in cytogenetically favorable-risk AML. In a smaller study in patients 15 to 50 years of age, no difference in survival was noted between 4 cycles of cytarabine at 3000 mg/m<sup>2</sup> and a combination of multiple cytotoxic agents.<sup>163</sup>

Altogether, there is no convincing evidence that cytarabine regimens at 3000 mg/m<sup>2</sup> are more effective than regimens at intermediate-dose levels at 1000 to 1500 mg/m<sup>2</sup>, with or without the addition of an anthracycline.<sup>147</sup> Open questions remain regarding the optimal number of cycles of consolidation therapy. In most studies, 2 to 4 cycles have been given after attainment of CR. In 1 randomized study, 2 cycles of postremission treatment following 2 induction cycles was not inferior to 3 postremission cycles.<sup>123</sup> Intensified postremission chemotherapy in high-risk patients, especially older patients is without clear benefit.<sup>164</sup>

**Intensive chemotherapy followed by autologous HCT.** One cycle of intensive chemotherapy followed by autologous HCT using peripheral blood CD34<sup>+</sup> cells offers condensed treatment. In 1 randomized study, autologous HCT provided better RFS and similar OS as conventional consolidation chemotherapy.<sup>165</sup> Recent data addressing the value of autologous HCT come from retrospective analyses accounting for the “lead time bias” consequent to the need for transplanted patients to live a minimum amount of time in order to receive a transplant. In these studies, autologous HCT leads to better EFS and RFS than chemotherapy.<sup>16,166,167</sup> This effect is mainly apparent in favorable- and intermediate-risk disease (mainly by 2010 ELN criteria) where outcome after autologous HCT approaches results after allogeneic HCT if OS is the end point. Limiting autologous HCT to patients who are MRD<sup>-</sup> might improve results.

**Maintenance therapy.** At the present time, maintenance chemotherapy is not part of standard AML treatment given a lack of convincing evidence of benefit.<sup>168,169</sup>

**Allogeneic HCT.** AML is the most frequent indication for allogeneic HCT with a 10% annual increase in transplants performed worldwide.<sup>170-172</sup> Expanded use of mismatched and unrelated donors as well as cord blood means a donor can be found for most patients. Furthermore, nonmyeloablative or reduced-intensity conditioning (RIC) regimens allow allogeneic HCT in patients aged up to 75 years. Nonetheless, in reality, only a minority of AML patients undergo transplantation because of older age, comorbidities, toxicity of prior therapy, inability to achieve a remission, and early relapse or refractory leukemia.<sup>173</sup>

**Indications.** The decision to perform allogeneic HCT depends on the assessment of the risk-benefit ratio (ie, nonrelapse mortality [NRM]/morbidity vs reduction of relapse risk) based on cytogenetic and molecular genetic features as well as patient, donor, and transplant factors.<sup>174-177</sup> AML with favorable-risk genetics are not a priori assigned to allogeneic HCT in first CR.<sup>57-59,77,174,177</sup> Allogeneic HCT is generally recommended when the relapse incidence without the procedure is expected to be >35% to 40%. The higher the expected relapse risk, the more risk of NRM may be accepted. Especially in the adverse genetic group, it is generally assumed, although not unambiguously demonstrated, that the transplant should be performed as soon as CR has been achieved. Allogeneic HCT is the only curative option for patients with primary refractory disease.

Sequential MRD monitoring by RT-qPCR or MFC provides a reliable guide to management. Patients with persistent MRD or with early MRD recurrence can receive salvage therapy and proceed to transplant before hematologic relapse, or may proceed directly to transplant depending on the likelihood of success with salvage therapy. Although allogeneic HCT often produces superior outcomes to chemotherapy it does not abrogate the negative effect of unfavorable genetics or pretransplant MRD.<sup>99,119</sup> Patients without MRD or adverse genetics but with high risk of NRM could receive chemotherapy only or autologous transplantation in CR1.<sup>167,178</sup>

**Myeloablative conditioning vs RIC.** RIC potentially extends the curative graft-versus-leukemia effect to patients of older age or to young patients with significant comorbidities.<sup>179-182</sup> Conditioning intensity varies. For instance, busulfan/fludarabine is more dose-intense than fludarabine/low-dose total-body irradiation.<sup>183</sup> Currently, >30% of allogeneic transplants are performed using RIC and have yielded encouraging results.<sup>184</sup> Although RIC and ablative conditioning have produced similar survival in patients aged 40 to 60 years in first CR,<sup>167</sup> a trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0901) randomizing 218 patients (+54 with MDS) aged 18 to 65 years and with HCT comorbidity index (HCT-CI) scores associated with <20% to 30% NRM between RIC (typically fludarabine/busulfan) and more ablative (typically busulfan/cyclophosphamide) regimens suggests an advantage for more ablative regimens.<sup>185</sup> This emphasizes the importance of randomized trials in transplantation with broad eligibility criteria to avoid selection bias. Currently, myeloablative regimens are generally recommended for healthy younger patients and RIC in elderly patients or in younger patients with severe comorbidities. Outcomes after myeloablative conditioning using busulfan/cyclophosphamide appear to be equivalent, if not superior, to outcomes after cyclophosphamide/total-body irradiation.<sup>186-188</sup>

**Comorbidities and risk scores.** Several transplant-related models have been developed to optimize decision-making about suitable candidates for allogeneic HCT.<sup>189</sup> The HCT-CI is a validated tool that sums a patient's comorbidities into a single score that predicts the likelihood of NRM given a myeloablative or RIC regimen.<sup>190</sup> A Disease Risk Index based on disease stage and cytogenetics has been developed that predicts the likelihood of disease recurrence following myeloablative or RIC regimens, independent of age, conditioning intensity, graft source, and donor type.<sup>191</sup> The modified European Society for Blood and Marrow Transplantation (EBMT) risk score was designed to predict OS rather than just NRM or relapse, and includes age, disease stage, donor source, gender mismatch, and time from diagnosis.<sup>192</sup> Recent reports suggest that a combination of the HCT-CI and the EBMT score may provide improved prediction of NRM and OS.<sup>193,194</sup>

**New modalities.** Partial or complete T-cell depletion and posttransplant cyclophosphamide may reduce the risks of acute and chronic graft-versus-host disease (GVHD).<sup>195-198</sup> The biggest challenge remains prevention of posttransplant relapse.<sup>199</sup> Preparative regimens including novel agents or radiolabeled monoclonal antibodies,<sup>200</sup> or therapy during the early posttransplant period with tyrosine kinase inhibitors or hypomethylating agents (HMAs) are being tested.<sup>201-203</sup> Furthermore, cell-based therapies are being developed to enhance the graft-versus-leukemia effect, such as natural killer cell enrichment or adoptive transfer, and the use of genetically engineered antigen-specific T cells that target AML-specific antigens.<sup>204-209</sup>

#### Older patients not considered candidates for intensive chemotherapy

Some AML patients will not tolerate intensive chemotherapy. Several risk scoring systems are available that use patient-specific and disease-specific factors to make the choice of intensive or alternative treatment.<sup>74,132,133,210</sup> The relevance of systems<sup>193,194</sup> originally designed to forecast NRM after allogeneic HCT is under investigation.<sup>211</sup>

Treatment alternatives for unfit patients are limited to best supportive care, low-intensity treatment, or clinical trials with investigational drugs. Low-intensity options are either low-dose cytarabine (LDAC) or therapy with HMA (Table 8). LDAC is generally well-tolerated and produces CR rates in the order of 15% to 25%; however, OS (median, 5-6 months) is unsatisfactory.<sup>212</sup>

Therapy with HMA has been evaluated in randomized trials. An increase in median OS with decitabine vs mostly LDAC (7.7 vs 5.0 months) was observed.<sup>213</sup> The AZA-AML-001 trial compared azacitidine with 3 conventional care regimens in patients aged  $\geq 65$  years with  $>30\%$  blasts: LDAC (158 patients), 7+3 (44 patients), or best supportive care only (45 patients)<sup>214</sup>; azacitidine increased the median survival (10.4 vs 6.5 months). Azacitidine may be particularly advantageous in AML with adverse cytogenetics.<sup>215</sup> Superiority of azacitidine over conventional care regimens was previously shown in AML with 20% to 30% blasts.<sup>216</sup> Up to 6 courses may be needed to observe maximal response with azacitidine or decitabine, although patients without response after 3 courses are unlikely to respond with further therapy.<sup>217</sup> HMA seem to alter the natural course of AML in some patients who do not achieve CR. Thus, hematologic improvement can also yield clinical benefit, that is, a reduction in transfusions and improved quality of life (QoL).

Treatment of unfit and most older patients with AML is currently unsatisfactory. We strongly recommend enrolling these patients in clinical trials.

## Relapsed disease and primary refractory disease

Treatment of patients with relapsed or primary refractory disease requires a balanced assessment of the likely benefit of further therapy vs the potential complications associated with salvage chemotherapy.<sup>218</sup>

#### Prognostic markers

Factors influencing survival were incorporated in the EPI score applicable to adults between 15 and 60 years of age.<sup>158</sup> Poor outcome is associated with shorter CR1 duration, increasing age at the time of relapse, nonfavorable karyotype at initial diagnosis, or history of prior allogeneic HCT.

#### Salvage treatment

No specific salvage regimen has emerged as the standard for treating primary refractory or relapsed AML.<sup>122,219-226</sup> Enrollment in a clinical trial should therefore be the priority for such patients whenever possible. Table 8 provides recommendations for salvage regimens in patients considered fit for intensive therapy.

In younger adults (16-49 years), a second CR can be achieved with intensive salvage therapy in about 55% in the absence of prior allogeneic HCT.<sup>227</sup> Two-thirds are able to proceed to allogeneic HCT in CR2, resulting in a 40% 5-year OS. Response rates are lower (~20%-30%) in more unselected adult patients with relapsed/refractory disease.<sup>222</sup> Benefit may also be derived from allogeneic HCT in the presence of active disease, with CR2 achieved in 42% and long-term survival observed in 9% to 22%.<sup>228-231</sup>

Another approach for patients with refractory or active disease is to use a short course of chemotherapy such as fludarabine, cytarabine, and amsacrine immediately prior to RIC and allogeneic HCT. With this approach, CR rates after allogeneic HCT of 70% to 90% are achieved, with expected 4-year survival ranging between 32% and 45%.<sup>231,232</sup> The possible constraint of selection bias should again be noted; nonetheless, at least 20% of patients with primary refractory disease can still be cured with allogeneic HCT.<sup>233</sup>

Outcome for patients relapsing after allogeneic HCT during first or second CR is particularly poor.<sup>234,235</sup> The Center for International Blood and Marrow Transplant Research (CIBMTR) recently found<sup>234</sup> 3-year OS was 4%, 12%, 26%, and 38% for relapses within 1 to 6 months, 6 months to 2 years, 2 to 3 years, and  $\geq 3$  years after allogeneic HCT, respectively. Lower mortality was independently associated with longer time from HCT to relapse and a first HCT using RIC; and inferior outcome associated with age  $>40$  years, active GVHD, adverse cytogenetics, mismatched unrelated donor, and use of cord blood for first HCT.<sup>234</sup> Outcomes may be better if patients receive chemotherapy to reduce disease burden followed by donor lymphocyte infusion, rather than chemotherapy alone.<sup>236,237</sup> Use of HMA has modest efficacy in AML relapsing post-HCT, producing CR rates of ~15%<sup>238</sup>; responses may be higher when combining donor lymphocyte infusion and azacitidine.<sup>239</sup> Responses have been observed in relapses after HCT, including extramedullary manifestations, using CTLA-4 blockade with ipilimumab.<sup>240</sup> The value of using a different donor for the second transplant remains unproven.<sup>235</sup>

In patients not fit for intensive salvage chemotherapy, effective treatment options are lacking. Azacitidine and decitabine induce CR rates of 16% to 21% and median survival times of 6 to 9 months in older patients with relapsed/refractory AML<sup>223-225</sup>; median postrelapse survival after therapy with LDAC is 5 to 6 months.<sup>226</sup> For

patients in second or third relapse, various therapeutic options are associated with CR rates of ~20% and median OS outcomes of ~3 months,<sup>221</sup> stressing the need for enrollment into clinical trials.

## Therapy-related AML

### Biology of t-AML

Therapy-related myeloid neoplasms (t-MNs) are a distinct category within the WHO classification including cases of t-MDS and t-AML. t-AML is a well recognized clinical syndrome occurring as a late complication following cytotoxic therapy for a primary neoplasm or a nonneoplastic disorder.<sup>241,242</sup> Currently comprising ~7% of all newly diagnosed AML, the incidence of t-AML is rising due to increasing numbers of cancer survivors at risk and changes in treatment.<sup>125,243,244</sup>

These neoplasms have been thought to be the direct consequence of mutational events induced by cytotoxic therapy. Association between type of prior exposure and phenotype of t-AML support a direct role of prior cytotoxic therapy. The more common subtype, seen in ~75% of patients, typically occurs 5 to 7 years after first exposure to alkylating agents or radiation, is often preceded by MDS, and is frequently accompanied by chromosomes 5 and/or 7 abnormalities, complex karyotype, and *TP53* mutation. In general, t-AML is associated with more adverse genetic lesions.<sup>245-248</sup> In a study analyzing mutation hotspots of 53 genes in 70 t-MNs (28 t-MDS, 42 t-AML), *TP53* was the most commonly mutated gene in t-MDS (35.7%) and t-AML (33.3%).<sup>248</sup> Some individuals develop t-AML after treatment with topoisomerase II inhibitors; their latency period is often only 1 to 3 years, antecedent MDS is rare, and balanced rearrangements involving *KMT2A (MLL)* at 11q23, *RUNX1* at 21q22, or *PML/RARA* are common. The distinction between these 2 subtypes has become less evident due to the use of multiagent chemotherapy, often in combination with radiotherapy.

An alternative mechanism is suggested by cases with a preexisting myeloid clone that is resistant to chemotherapy.<sup>249</sup> Cases of t-AML were identified in which the exact *TP53* mutation found at diagnosis was already present at low frequency in blood or bone marrow many years before t-AML development.<sup>249</sup> Similarly, somatic mutations in *PPM1D*, a serine/threonine phosphatase that negatively regulates p53,<sup>250</sup> have been found in blood of patients with breast, ovarian, and lung cancer.<sup>251-254</sup> In ovarian cancer, the frequency of *PPM1D* mutations in blood was significantly associated with prior chemotherapy, and the variant allele frequency increased during chemotherapy.<sup>251</sup> These data suggest a model in which hematopoietic progenitor cells carrying mutations in the *TP53* pathway undergo selective pressure by cytotoxic therapy, ultimately leading to t-AML.

Some cases of t-MNs have been shown to be associated with germ line mutations in cancer susceptibility genes.<sup>255,256</sup> In a recent study of survivors of breast cancer developing t-AML, many patients had personal or family histories suggestive of inherited cancer susceptibility; 10 of 41 patients studied (21%) carried germ line mutations in *BRCA1*, *BRCA2*, *TP53*, or *CHEK2* genes.<sup>256</sup> The identification of such preexisting conditions will facilitate screening and counseling of patients prior to treatment of their primary disease.

### Treatment of t-AML

The survival of patients with t-MNs has remained poor mainly due to sequelae of prior therapy, and to adverse disease-related features.<sup>257-261</sup> Therapy may be compromised by a higher treatment-related morbidity

and mortality.<sup>259</sup> There is still little prospective treatment data because these patients have often been excluded from frontline clinical trials. Clinical trials should allow enrollment of patients with t-MN. Allogeneic HCT should be considered, due to the poor results with conventional chemotherapy.

## Clinical trials

### Necessity for biobanking

We strongly recommend storage of biosamples (see “Biobanking”) be done in all clinical trials. Such biobanking can be performed as part of an interventional trial, or within a noninterventional biobanking or registry study.

### Trial design

Trials of new therapies have traditionally been disease-specific, proceeding through phase 1 (determination of maximum tolerated dose [MTD]), phase 2 (determination of efficacy), and phase 3 (randomized comparison of new and standard therapies). Recent challenges to this paradigm have arisen.

**Early drug development.** “Basket trials.” Basket trials test therapies that target a specific genetic mutation or a deregulated pathway found in a tumor regardless of its origin. Enrollment might include patients with AML and other tumor types provided their cells contain the aberration.<sup>262,263</sup>

**MTD vs “optimal biologic dose.”** When a drug’s ability to modulate its target appears fundamental to its clinical activity, phase 1 studies might seek to identify the optimal biologic dose (OBD) rather than the MTD. Randomization between OBD and MTD might be considered in phase 2 to shed light on which approach is preferable.<sup>262</sup>

**Combined phase 1-2 designs.** To accelerate drug development, many phase 1 protocols now include an expansion phase which focuses on efficacy.<sup>264</sup> On the assumption of a relation between efficacy and toxicity, multiple outcome designs simultaneously base dose finding on toxicity and efficacy, with a dose declared admissible for further study if associated with relatively low probabilities of toxicity and high probabilities of efficacy.<sup>265</sup>

**“Pick-a-winner designs” to accelerate drug development.** The conventional distinction between the single-arm phase 2 trial and the larger (randomized) phase 3 study has been questioned. The frequent failure of therapies found “promising” in single-arm phase 2 trials to translate into truly successful treatments because of various biases in phase 2 is well known.<sup>266</sup> Because these biases can only be addressed by randomization, there has been increasing interest in randomized phase 2 designs, also known as “selection” or “pick-a-winner” designs.<sup>267,268</sup> Here, randomization between a standard and a new treatment begins sooner than currently. A first stage enrolls a relatively small number of patients, thus allowing more agents to be investigated in a given time. Treatments that meet a particular efficacy criterion are carried forward against the standard into a larger second stage, analogous to standard phase 3 studies, whereas treatments not meeting these criteria drop out. One limitation of the design is that small sample sizes may preclude the identification of patients with biologically defined subsets of the disease that may benefit from a particular new agent.

**Adaptive designs.** Adaptive designs use incoming information from the early stages of a trial to affect conduct of later stages.<sup>269,270</sup> Although designs such as the 3+3 and the Simon 2-stage are technically

“adaptive,” newer designs make more frequent use of incoming information. An example is “adaptive randomization” in which patients are initially randomized 1:1 after which randomization probabilities change at various intervals, to reflect incoming results.<sup>269</sup> An advantage is that fewer patients may receive an ultimately unsatisfactory therapy, whereas a disadvantage is a loss of power. Another example is the continuous reassessment method, which in phase 1 trials permits more account to be made of covariates other than dose than does the standard 3+3 design.<sup>271</sup>

### End points

**OS and EFS.** Table 7 lists outcome measures, and Table 9 recommended reporting criteria for phase 3 clinical trials. OS is the end point most commonly used for approval of new therapies. However, OS may be an imperfect indicator of a new drug’s efficacy because advances in rescue therapies and supportive care have made it possible to keep patients alive after AML has relapsed or failed to enter CR.<sup>262,272</sup> In contrast, EFS includes relapse and failure to enter CR as well as death and thus may better reflect a single treatment’s efficacy.<sup>272-275</sup> Furthermore, less time is required to assess EFS, and use of EFS facilitates crossover designs, that is, patients are randomly assigned to a sequence of treatments.

**Incorporation of MRD.** The utility of CR as a surrogate for OS has been questioned.<sup>276,277</sup> Likewise, if CRs are short-lived, a higher CR rate may not result in meaningful improvements in EFS. Considerable evidence indicates that patients in CR by conventional criteria who have MRD as assessed by RT-qPCR or MFC are at higher risk of relapse and death than patients without MRD (see “Monitoring of minimal residual disease”). This suggests the potential utility of CR<sub>MRD-</sub> as a rapidly assessable end point that may serve as a surrogate for EFS or long-term survival provided these relationships can be confirmed and means to measure MRD can be harmonized.<sup>91,92</sup>

**QoL.** Regulatory drug approval agencies accept improvement in QoL as well as in quantity of life as a criterion for new drug approval. Although QoL has received little attention, clinical observation suggests that patients who achieve CR may have improved QoL, for example, due to receipt of fewer transfusions and spending less time in medical facilities than patients who do not achieve CR, even if survival is not improved; the same may apply with CRi.<sup>278</sup>

## Novel therapies

AML is an important field for new drug investigation.<sup>2,262,279</sup> Novel therapies are usually first evaluated in patients with relapsed/refractory disease or in older patients not considered candidates for standard intensive chemotherapy. Novel therapies in preclinical or clinical development may be categorized as protein kinase inhibitors, epigenetic modulators, new cytotoxic agents, mitochondrial inhibitors including apoptosis therapies, therapies targeting specific oncogenic proteins, therapeutic and immune checkpoint antibodies and cellular immunotherapies, and therapies targeting the AML microenvironment (Table 10).

Efforts to develop protein kinase inhibitors, inhibiting mutated forms of the FLT3 receptor have led to successive generations of FLT3 inhibitors.<sup>280</sup> The first generation comprised tandutinib, sunitinib, lestaurtinib, sorafenib, and midostaurin, and the next generation quizartinib, crenolanib, and gilteritinib. These compounds differ not

**Table 9. Recommended minimum reporting criteria for phase 3 clinical trials**

Reporting objective	Reporting end point
Response rate	<ul style="list-style-type: none"> <li>• CR/CR<sub>i</sub> achieved at completion of induction cycle 1 (%)</li> <li>• CR/CR<sub>i</sub> rate after completion of all induction cycles (%)</li> </ul>
Treatment failure	<ul style="list-style-type: none"> <li>• Primary refractory disease (%) as indicated by failure to achieve CR/CR<sub>i</sub> after completing induction therapy (2 cycles)</li> <li>• % Death from any cause within 30 d</li> <li>• % Death from any cause within 60 d</li> </ul>
RFS	<ul style="list-style-type: none"> <li>• Median RFS from date of CR to relapse (mo)</li> <li>• 1-y/3-y/5-y RFS (%)</li> </ul>
EFS	<ul style="list-style-type: none"> <li>• Median EFS (mo)</li> <li>• 1-y/3-y/5-y EFS (%)</li> </ul>
OS*	<ul style="list-style-type: none"> <li>• Median OS (mo)</li> <li>• 1-y/3-y/5-y OS (%)</li> </ul>
Time to neutrophil recovery	<ul style="list-style-type: none"> <li>• No. of days from day 1 of commencing induction therapy to first day neutrophils <math>0.5 \times 10^9/L</math></li> <li>• No. of days from day 1 of commencing induction therapy to first day neutrophils <math>1.0 \times 10^9/L</math></li> </ul>
Time to platelet recovery	<ul style="list-style-type: none"> <li>• No. of days from day 1 of commencing induction therapy to first day platelets <math>50 \times 10^9/L</math></li> <li>• No. of days from day 1 of commencing induction therapy to first day platelets <math>100 \times 10^9/L</math></li> </ul>

\*OS should also be reported with patients censored on day 0 of allogeneic HCT.

only in their ability to inhibit FLT3-ITD or tyrosine kinase domain or even the wild-type receptor, but also in their selectivity for FLT3 as well as their toxicity profiles. As discussed in “Intensive induction therapy,” the phase 3 trial evaluating midostaurin in younger adult patients with *FLT3* mutations reached its primary end point, improvement of OS.<sup>61</sup> Randomized trials evaluating intensive chemotherapy with other FLT3 inhibitors, such as lestaurtinib and sorafenib, failed to show an improvement in response rate and in OS.<sup>281-284</sup> The trial with sorafenib in younger patients (not restricted to AML with *FLT3* mutations) showed an improvement in EFS, mainly reflecting results in patients without *FLT3*-ITD, that did not translate into a significant OS benefit.<sup>284</sup> Randomized trials evaluating next-generation FLT3 inhibitors are ongoing.

Another rapidly expanding area is development of novel epigenetic therapies.<sup>285,286</sup> Guadecitabine (SGI-110) is a second-generation HMA currently in phase 3 development.<sup>287</sup> Guadecitabine is a dinucleotide of decitabine and deoxyguanosine that increases the in vivo exposure of decitabine by protecting it from inactivation by cytidine deaminase. One novel targeted approach is the inhibition of the metabolic enzymes IDH1 and IDH2 that are frequently mutated in AML.<sup>288</sup> Early trial results with these inhibitors show durable responses and appear promising.<sup>289,290</sup> Other examples are targeting of BRD4, a member of the BET family of bromodomain epigenetic readers,<sup>291</sup> or of *KMT2A* (*MLL*)–rearranged leukemias.<sup>292,293</sup>

In a randomized trial conducted in patients with relapsed and refractory AML, the topoisomerase II inhibitor vosaroxin in combination with IDAC demonstrated a small survival benefit in patients older than 60 years (7.1 vs 5.0 months); a benefit was not shown in younger patients, potentially due to the higher transplant rate (45.8% <60 years vs 20.2% ≥60 years).<sup>222</sup>

Finally, targeted immunotherapy is an important novel approach.<sup>294</sup> A variety of therapeutic antibodies directed against AML antigenic targets (eg, CD33, CD123, CLEC12A), bispecific T-cell engagers, or dual-affinity retargeting molecules as well as engineered chimeric



**Table 10. Novel therapies in clinical development in AML**

Novel therapies in clinical development	
Protein kinase inhibitors	<ul style="list-style-type: none"> <li>• FLT3 inhibitors (midostaurin, quizartinib, gilteritinib, crenolanib)</li> <li>• KIT inhibitors</li> <li>• PI3K/AKT/mTOR inhibitors</li> <li>• Aurora and polo-like kinase inhibitors, CDK4/6 inhibitors, CHK1, WEE1, and MPS1 inhibitors</li> <li>• SRC and HCK inhibitors</li> </ul>
Epigenetic modulators	<ul style="list-style-type: none"> <li>• New DNA methyltransferase inhibitors (SGI-110)</li> <li>• HDAC inhibitors</li> <li>• IDH1 and IDH2 inhibitors</li> <li>• DOT1L inhibitors</li> <li>• BET-bromodomain inhibitors</li> </ul>
Chemotherapeutic agents	<ul style="list-style-type: none"> <li>• CPX-351</li> <li>• Vosaroxin</li> <li>• Nucleoside analogs</li> </ul>
Mitochondrial inhibitors	<ul style="list-style-type: none"> <li>• Bcl-2, Bcl-xL, and Mcl-1 inhibitors</li> <li>• Caseolytic protease inhibitors</li> </ul>
Therapies targeting oncogenic proteins	<ul style="list-style-type: none"> <li>• Fusion transcripts targeting</li> <li>• EVI1 targeting</li> <li>• NPM1 targeting</li> <li>• Hedgehog inhibitors</li> </ul>
Antibodies and immunotherapies	<ul style="list-style-type: none"> <li>• Monoclonal antibodies against CD33, CD44, CD47, CD123, CLEC12A</li> <li>• Immunoconjugates (eg, GO, SGN33A)</li> <li>• BiTEs and DARTs</li> <li>• CAR T cells or genetically engineered TCR T cells</li> <li>• Immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4)</li> <li>• Anti-KIR antibody</li> <li>• Vaccines (eg, WT1)</li> </ul>
Therapies targeting AML environment	<ul style="list-style-type: none"> <li>• CXCR4 and CXCL12 antagonists</li> <li>• Antiangiogenic therapies</li> </ul>

BiTE, bispecific T-cell engager; CAR, chimeric antigen receptor; DART, dual-affinity retargeting molecule; HDAC, histone deacetylase; KIR, killer-cell immunoglobulin-like receptor; mTOR, mechanistic target of rapamycin; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PI3K, phosphatidylinositol 3-kinase; TCR, T-cell receptor.

antigen receptor T cells targeting the CD33 and CD123 antigens are currently in early clinical trial.

## Management of special situations

### Hyperleukocytosis

A recent systematic review assessed early mortality in patients with an initial white blood cell count  $\geq 100 \times 10^9/L$  and found neither leukapheresis nor hydroxyurea/low-dose chemotherapy influenced the early death rate.<sup>295</sup> Hyperleukocytosis reflects a medical emergency. After immediate diagnostic testing, patients should begin cytoreductive treatment without delay preferably with the planned induction regimen.

### Others

There have been no new developments in management of central nervous system (CNS) AML, myeloid sarcoma, or pregnancy in AML since the 2010 ELN publication and readers are referred there for information.<sup>1</sup>

## Supportive care

### Prophylactic anti-infectious treatment

For prophylaxis and treatment of infections, prevailing institutional infectious organisms and their drug-resistance pattern should primarily be considered. As noted in the 2010 ELN recommendations, prophylaxis with a quinolone should be given.<sup>1</sup>

A systematic survey of randomized trials in AML found “high-level evidence” supporting use of posaconazole to prevent invasive fungal infections during remission induction therapy and in patients with GVHD after allogeneic HCT. Micafungin can be used when azoles are strictly prohibited, although fluconazole is generally acceptable because it has a very low interaction with CYP3A4. There was insufficient evidence to guide antifungal prophylaxis in patients undergoing allogeneic HCT without GVHD or other high-risk factors.<sup>296</sup>

### Other issues

There have been few new developments regarding use of myeloid growth factors or transfusion support since the 2010 ELN recommendations to which the reader is referred.<sup>1</sup> Neither growth factors nor granulocyte transfusions can be recommended outside of the individual patient setting. In 2 randomized trials comparing prophylactic (at a count  $< 10 \times 10^9/L$ ) vs therapeutic (only if bleeding) platelet transfusion, more grade 2-4 bleeding occurred in the therapeutic arms together with a slight excess in fatal (CNS) hemorrhage.<sup>297,298</sup> Thus, prophylactic platelet transfusion at a count  $< 10 \times 10^9/L$  remains the standard for patients with AML.

## Acknowledgments

The authors gratefully acknowledge Rüdiger Hehlmann for his continuous generous support of these recommendations on behalf of the European LeukemiaNet; Adam Ivey and Elli Papaemmanuil for their support in generating Figure 1; and Lucy Godley and Rafael Bejar for reviewing the section on myeloid neoplasms with germ line predisposition.

H. Döhner was supported by SFB 1074 “Experimental models and clinical translation in leukemia” funded by the Deutsche Forschungsgemeinschaft (DFG). D.G. was grateful for support from the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (grant reference RP-PG-0108-10093). J.S. was supported by grants from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 2014SGR-1281, Instituto de Salud Carlos III (ISCIII) RD12/0036/0071 and Fondo de Investigación en Salud (FIS) PI14/00450. F.L.-C. was supported by Associazione Italiana per la Ricerca sul Cancro grant AIRC I.G. 5916. C.D.B. was supported by National Institutes of Health National Cancer Institute grants CA180861, CA016058.

## Authorship

Contribution: All authors reviewed the literature and wrote first drafts of specific sections; H. Döhner and C.D.B. assembled the sections and wrote the final version of the manuscript; and all authors reviewed and approved the final version of the manuscript.

Conflict-of-interest disclosure: H. Döhner provided consultancy services to Agios, Amgen, Astex Pharmaceuticals, Celator, Celgene,

Novartis, Roche, Seattle Genetics, Sunesis, and Tolero, and received research funding from Boehringer Ingelheim, Celgene, Novartis, Bristol-Myers Squibb, and Arog Pharmaceuticals. S.A. provided consultancy services to Amgen and Daiichi Sankyo. H. Dombret provided consultancy services to Roche/Genentech, Amgen, Pfizer, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Sunesis, Ambit, Daiichi Sankyo, Karyopharm, Kite Pharma, Menarini, Astellas, Janssen, Servier, and Seattle Genetics, and received research funding from Roche/Genentech, Amgen, Ariad, Jazz Pharmaceuticals, and Kite Pharma. B.L.E. provided consultancy services to Celgene, Genoptix, and H3 Biomedicine, and received research funding from Celgene. P.F. provided consultancy services to Celgene, Novartis, and Teva, and received research funding from Celgene, Janssen, Novartis, Astex, and Teva. R.A.L. provided consultancy services to Novartis, Ariad, CVS/Caremark, Erytech, Pfizer, Celgene, and Bristol-Myers Squibb, and received research funding from Astellas, Erytech, Novartis, and Daiichi Sankyo. R.L.L. provided consultancy services to Novartis and served on the supervisory board for Qiagen. F.L.-C. provided consultancy services to Teva and Novartis, received honoraria from Teva and Lundbeck, and received research support from Teva and Novartis. D.N. received research funding from Novartis and Amgen, and served on the speakers' bureaus for

Novartis and Amgen. G.J.O. provided consultancy services to Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Sunesis, Celgene, Karyopharm, and Amgen, and received research support from Novartis, Johnson & Johnson, Celgene, Immunogene, and Becton Dickinson. J.S. provided consultancy services to Celgene, Novartis, Sunesis, Karyopharm, Pfizer, Janssen, and Meda Pharmaceuticals; received research support from Celgene, Novartis, and Amgen; was a speaker for Celgene, Pfizer, and Janssen; and was a member of the Board of Directors for the European Haematology Association, the Spanish Society of Hematology, and the José Carreras International Leukemia Foundation. A.H.W. provided consultancy services to Novartis, Celgene, Servier, Abbvie, Roche, Amgen, and CTI, and received research funding from Abbvie, Novartis, Celgene, Servier, Ariad, and Amgen. B.L. provided consultancy services to Celgene, Agios, AstraZeneca, and Astex, and was a Section Editor for *Leukemia*. The remaining authors declare no competing financial interests.

Thomas Büchner died on 5 August 2016. David Grimwade died on 17 October 2016.

Correspondence: Hartmut Döhner, Department of Internal Medicine III, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany; e-mail: hartmut.doehner@uniklinik-ulm.de.

## References

- Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010;115(3):453-474.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. *N Engl J Med*. 2015;373(12):1136-1152.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
- Arber DA, Vardiman JW, Brunning RD, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Update to 4th Edition. Lyon, France: World Health Organization. In press.
- Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*. 2009;113(9):1875-1891.
- Peterson L, Bloomfield CD, Döhner H, Niemeyer C, Godley L. Myeloid neoplasms with germline predisposition. In: Swerdlow S, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Update to 4th Edition. Lyon, France: World Health Organization. In press.
- Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell*. 2014;157(2):369-381.
- Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. *Cancer Cell*. 2014;25(4):415-427.
- Nacheva EP, Grace CD, Brazza D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? *Br J Haematol*. 2013;161(4):541-550.
- Wouters BJ, Löwenberg B, Erpelink-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009;113(13):3088-3091.
- Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. *Br J Cancer*. 2009;100(8):1343-1346.
- Hou HA, Lin LI, Chen CY, Tien HF. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. *Br J Cancer*. 2009;101(4):738-740.
- Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. *J Clin Oncol*. 2010;28(16):2739-2747.
- Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. *J Clin Oncol*. 2010;28(4):570-577.
- Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood*. 2011;117(8):2469-2475.
- Schlenk RF, Taskesen E, van Norden Y, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*. 2013;122(9):1576-1582.
- Falini B, Maciejewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). *Blood*. 2010;115(18):3776-3786.
- Díaz-Beyá M, Rozman M, Pratcorona M, et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. *Blood*. 2010;116(26):6147-6148.
- Bacher U, Schnittger S, Maciejewski K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. *Blood*. 2012;119(20):4719-4722.
- Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. *Blood*. 2009;114(26):5352-5361.
- Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. *J Clin Oncol*. 2011;29(10):1364-1372.
- Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. *J Clin Oncol*. 2012;30(25):3109-3118.
- Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. *Leukemia*. 2016;30(11):2160-2168.
- Haferlach T, Stengel A, Eckstein S, et al. The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia. *Leukemia*. 2016;30(10):2109-2112.
- Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. *Blood*. 2009;114(14):3024-3032.
- Walter RB, Othous M, Burnett AK, et al. Significance of FAB subclassification of "acute

- myeloid leukemia, NOS<sup>a</sup> in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. *Blood*. 2013;121(13):2424-2431.
27. Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. *Blood*. 2016;128(14):1800-1813.
  28. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. *Cancer Cell*. 2015;27(5):658-670.
  29. Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. *Nat Genet*. 2015;47(2):180-185.
  30. Harutyunyan AS, Giambruno R, Krendl C, et al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. *Blood*. 2016;127(3):362-365.
  31. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.
  32. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. *N Engl J Med*. 2010;363(25):2424-2433.
  33. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat Genet*. 2011;43(4):309-315.
  34. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell*. 2012;150(2):264-278.
  35. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature*. 2012;481(7382):506-510.
  36. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366(12):1079-1089.
  37. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.
  38. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. *Sci Transl Med*. 2012;4(149):149ra118.
  39. Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. *Blood*. 2013;122(1):100-108.
  40. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc Natl Acad Sci USA*. 2014;111(7):2548-2553.
  41. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in *Nature*. 2014;508(7496):420]. *Nature*. 2014;506(7488):328-333.
  42. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet*. 2012;44(11):1179-1181.
  43. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
  44. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med*. 2014;20(12):1472-1478.
  45. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371(26):2477-2487.
  46. McKerrill T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell Reports*. 2015;10(8):1239-1245.
  47. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
  48. Béné MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. *Leukemia*. 2011;25(4):567-574.
  49. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood*. 2010;116(3):354-365.
  50. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. *Blood*. 2016;127(1):29-41.
  51. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. *Blood*. 2011;118(24):6247-6257.
  52. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. *Blood*. 2011;118(13):3645-3656.
  53. Thol F, Kölling B, Hollink IH, et al. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. *Leukemia*. 2013;27(3):750-754.
  54. Gruber TA, Larson Gedman A, Zhang J, et al. An Inv(16)(p13.3q24.3)-encoded CBF2A2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. *Cancer Cell*. 2012;22(5):683-697.
  55. McKerrill T, Moreno T, Pongstingl H, et al. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. *Blood*. 2016;128(1):e1-e9.
  56. He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. *Blood*. 2016;127(24):3004-3014.
  57. Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. *Blood*. 2008;111(5):2776-2784.
  58. Pratorcora M, Brunet S, Nomdedéu J, et al; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Favorable outcome of patients with acute myeloid leukemia harboring a low-allopathic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. *Blood*. 2013;121(14):2734-2738.
  59. Schlenk RF, Kayser S, Bullinger L, et al; German-Austrian AML Study Group. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. *Blood*. 2014;124(23):3441-3449.
  60. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. *Blood*. 2014;124(2):273-276.
  61. Stone RM, Mandrekar S, Laumann C, et al. Midostaurin, a multi-targeted kinase inhibitor, improves overall survival when added to standard chemotherapy in adults age 18 – 60 with FLT3 mutant acute myeloid leukemia (AML): results from a randomized, prospective, placebo-controlled, double-blind trial, CALGB 10603/RATIFY [abstract]. *Blood*. 2015;126(23):Abstract 6.
  62. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. *Blood*. 2011;118(26):6920-6929.
  63. Pratorcora M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. *Haematologica*. 2012;97(3):388-392.
  64. Schnitger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. *Leukemia*. 2013;27(1):82-91.
  65. Paschka P, Schlenk RF, Gaidzik VI, et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. *Haematologica*. 2015;100(3):324-330.
  66. Haferlach C, Dicker F, Herholz H, Schnitger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. *Leukemia*. 2008;22(8):1539-1541.
  67. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. *Leukemia*. 2009;23(1):203-206.
  68. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood*. 2012;119(9):2114-2121.
  69. Devillier R, Mansat-De Mas V, Gelsi-Boyer V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. *Oncotarget*. 2015;6(10):8388-8396.
  70. Tsai CH, Hou HA, Tang JL, et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. *Leukemia*. 2016;30(7):1485-1492.
  71. Churpek JE, Pyrtel K, Kanchi KL, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*. 2015;126(22):2484-2490.
  72. Mujahed H, Stefan D, Lehmann S. Bone marrow fibroblasts derived from vitally frozen mononuclear cells as a source for germ line DNA in acute myeloid leukemia (AML) [abstract]. *Blood*. 2015;126(23):Abstract 2606.
  73. Metzeler KH, Herold T, Rothenberg-Thurley M, et al; AMLCG Study Group. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood*. 2016;128(5):686-698.
  74. Walter RB, Othous M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *J Clin Oncol*. 2011;29(33):4417-4423.

75. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. *J Clin Oncol*. In press.
76. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. *Lancet Oncol*. 2014;15(9):e382-e394.
77. Ho AD, Schetelig J, Bochtler T, et al; Study Alliance Leukemia. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. *Biol Blood Marrow Transplant*. 2016;22(3):462-469.
78. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616-3627, quiz 3699.
79. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. 2014;28(2):241-247.
80. Taskesen E, Havermans M, van Lom K, et al. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. *Blood*. 2014;123(21):3327-3335.
81. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*. 2015;125(9):1367-1376.
82. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia*. 2013;27(9):1861-1869.
83. Paschka P, Döhner K. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? *Hematology Am Soc Hematol Educ Program*. 2013;2013:209-219.
84. Allen C, Hills RK, Lamb K, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. *Leukemia*. 2013;27(9):1891-1901.
85. Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*. 2013;121(12):2213-2223.
86. Paschka P, Du J, Schlenk RF, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). *Blood*. 2013;121(1):170-177.
87. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. *Blood*. 2016;127(20):2451-2459.
88. Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. *Nat Genet*. 2016;48(12):1551-1556.
89. Micol JB, Duployez N, Boissel N, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. *Blood*. 2014;124(9):1445-1449.
90. Lavallée VP, Kros J, Lemieux S, et al. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. *Blood*. 2016;127(24):3054-3061.
91. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? *Blood*. 2014;124(23):3345-3355.
92. Ossenkoppele GJ, Schuurhuis GJ. MRD in AML: it is time to change the definition of remission. *Best Pract Res Clin Haematol*. 2014;27(3-4):265-271.
93. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. *Blood*. 2010;116(13):2295-2303.
94. Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. *J Clin Oncol*. 2012;30(29):3625-3632.
95. Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood*. 2012;120(8):1581-1588.
96. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. *J Clin Oncol*. 2013;31(32):4123-4131.
97. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol*. 2013;31(31):3889-3897.
98. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *J Clin Oncol*. 2015;33(11):1258-1264.
99. Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? *J Clin Oncol*. 2016;34(4):329-336.
100. Scholl C, Schlenk RF, Eiwien K, Döhner H, Fröhling S, Döhner K; AML Study Group. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. *Haematologica*. 2005;90(12):1626-1634.
101. Schnittger S, Kern W, Tschulic C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. *Blood*. 2009;114(11):2220-2231.
102. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J Clin Oncol*. 2011;29(19):2709-2716.
103. Shayegi N, Kramer M, Bornhäuser M, et al; Study Alliance Leukemia (SAL). The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. *Blood*. 2013;122(1):83-92.
104. Hubmann M, Köhnke T, Hoster E, et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. *Haematologica*. 2014;99(8):1317-1325.
105. Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. *Oncotarget*. 2014;5(15):6280-6288.
106. Ivey A, Hills RK, Simpson MA, et al; UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. *N Engl J Med*. 2016;374(5):422-433.
107. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFb-MYH11-positive acute myeloid leukemia. *J Clin Oncol*. 2010;28(23):3724-3729.
108. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. *Blood*. 2012;120(14):2826-2835.
109. Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. *Blood*. 2013;121(20):4056-4062.
110. Kohlmann A, Nadarajah N, Alpermann T, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. *Leukemia*. 2014;28(1):129-137.
111. Kloco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. *JAMA*. 2015;314(8):811-822.
112. Pløen GG, Nelderby L, Guldborg P, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. *Br J Haematol*. 2014;167(4):478-486.
113. Gaidzik V, Weber D, Paschka P, et al. Monitoring of minimal residual disease (MRD) of DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): a study of the AML Study Group (AMLSG) [abstract]. *Blood*. 2015;126(23). Abstract 226.
114. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. *J Clin Oncol*. 2012;30(36):4515-4523.
115. Micol JB, Boissel N, Renneville A, et al. The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. *Blood*. 2009;114(20):4601-4602, author reply 4602-4603.
116. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *J Clin Oncol*. 2008;26(29):4791-4797.
117. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. *Blood*. 2010;116(13):2224-2228.
118. Kayser S, Zucknick M, Döhner K, et al; German-Austrian AML Study Group. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. *Blood*. 2012;119(2):551-558.
119. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. *J Clin Oncol*. 2012;30(17):2140-2146.
120. Pasquini MC, Zhang MJ, Medeiros BC, et al. Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies. *Biol Blood Marrow Transplant*. 2016;22(2):248-257.
121. Othus M, Mukherjee S, Sekeres MA, et al. Prediction of CR following a second course of

- '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. *Leukemia*. 2016;30(8):1779-1780.
122. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. *Blood*. 2010;116(26):5818-5823, quiz 6153.
  123. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. *J Clin Oncol*. 2013;31(27):3360-3368.
  124. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med*. 2011;364(26):2496-2506.
  125. Granfeldt Östgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. *J Clin Oncol*. 2015;33(31):3641-3649.
  126. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. *J Clin Oncol*. 2012;30(27):3376-3382.
  127. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. *J Clin Oncol*. 2014;32(25):2691-2698.
  128. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.
  129. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.
  130. Krug U, Röhlig C, Koschmieder A, et al; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. *Lancet*. 2010;376(9757):2000-2008.
  131. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer*. 2006;106(5):1090-1098.
  132. Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2014;2014(1):8-13.
  133. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. *Blood*. 2013;121(21):4287-4294.
  134. Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. *Haematologica*. 2013;98(2):208-216.
  135. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. *Br J Haematol*. 2007;136(4):624-627.
  136. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. *Leukemia*. 2014;28(2):289-292.
  137. Sorror M, Storer B, Elsayy M, et al. Relative benefit for intensive versus non-intensive induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) using a composite, age-comorbidity-cytogenetic, model [abstract]. Presented at the 21st Congress of the European Hematology Association. 11 June 2016. Copenhagen, Denmark. Abstract LB580.
  138. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. *Blood*. 2016;127(1):53-61.
  139. Löwenberg B, Ossenkoppele GJ, van Putten W, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in *N Engl J Med*. 2010;362(12):1155]. *N Engl J Med*. 2009;361(13):1235-1248.
  140. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009;361(13):1249-1259.
  141. Lee JH, Joo YD, Kim H, et al; Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood*. 2011;118(14):3832-3841.
  142. Burnett AK, Russell NH, Hills RK, et al; UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m<sup>2</sup> vs 60 mg/m<sup>2</sup> in AML induction: results from the UK NCRI AML17 trial in 1206 patients. *Blood*. 2015;125(25):3878-3885.
  143. Burnett AK, Russell NH, Hills RK; United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. *Blood*. 2016;128(3):449-452.
  144. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. *J Clin Oncol*. 2010;28(5):808-814.
  145. Löwenberg B, Pabst T, Vellenga E, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. *N Engl J Med*. 2011;364(11):1027-1036.
  146. Willemze R, Suci S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J Clin Oncol*. 2014;32(3):219-228.
  147. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. *Blood*. 2013;121(1):26-28.
  148. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood*. 2013;121(24):4854-4860.
  149. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. *J Clin Oncol*. 2011;29(4):369-377.
  150. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. *J Clin Oncol*. 2012;30(32):3924-3931.
  151. Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet*. 2012;379(9825):1508-1516.
  152. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*. 2014;15(9):986-996.
  153. Amadori S, Suci S, Stasi R, et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). *J Clin Oncol*. 2013;31(35):4424-4430.
  154. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. *Mol Cancer Ther*. 2006;5(7):1854-1863.
  155. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. *Blood*. 2014;123(21):3239-3246.
  156. Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. *Cancer*. 2015;121(2):234-242.
  157. Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML [abstract]. *J Clin Oncol*. 2016;34(suppl). Abstract 7000.
  158. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol*. 2005;23(9):1969-1978.
  159. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. *J Clin Oncol*. 2012;30(20):2441-2448.
  160. Burnett AK, Russell NH, Hills RK, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia [published online ahead of print 30 September 2016]. *Leukemia*. doi:10.1038/leu.2016.225.
  161. Schaich M, Röhlig C, Soucek S, et al. Cytarabine dose of 36 g/m<sup>2</sup> compared with 12 g/m<sup>2</sup> within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. *J Clin Oncol*. 2011;29(19):2696-2702.
  162. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid

- leukemia in adults: the JALSG AML201 Study. *Blood*. 2011;117(8):2366-2372.
163. Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. *Blood*. 2011;118(7):1754-1762.
  164. Itzykson R, Gardin C, Pautas C, et al; Acute Leukemia French Association (ALFA). Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. *Haematologica*. 2011;96(6):837-844.
  165. Vellenga E, van Putten W, Ossenkoppele GJ, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. *Blood*. 2011;118(23):6037-6042.
  166. Pffirmann M, Ehninger G, Thiede C, et al; Study Alliance Leukaemia (SAL). Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. *Lancet Oncol*. 2012;13(2):207-214.
  167. Cornelissen JJ, Versluis J, Passweg JR, et al; HOVON; SAKK Leukemia Groups. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. *Leukemia*. 2015;29(5):1041-1050.
  168. Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. *Blood*. 2011;117(26):7007-7013.
  169. Löwenberg B, Beck J, Graux C, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood*. 2010;115(13):2586-2591.
  170. Gratwohl A, Pasquini MC, Aljurf M, et al; Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. *Lancet Haematol*. 2015;2(3):e91-e100.
  171. Passweg JR, Baldomero H, Bader P, et al; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. *Bone Marrow Transplant*. 2015;50(4):476-482.
  172. Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. *Bone Marrow Transplant*. 2016;51(6):778-785.
  173. Juliusson G, Karlsson K, Lazarevic VL, et al; Swedish Acute Leukemia Registry Group, the Swedish Acute Myeloid Leukemia Group, the Swedish Adult Acute Lymphoblastic Leukemia Group. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. *Cancer*. 2011;117(18):4238-4246.
  174. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol*. 2012;9(10):579-590.
  175. Majhail NS, Farnia SH, Carpenter PA, et al; American Society for Blood and Marrow Transplantation. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(11):1863-1869.
  176. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. *Bone Marrow Transplant*. 2015;50(8):1037-1056.
  177. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. *Blood*. 2016;127(1):62-70.
  178. Gorin NC, Giebel S, Labopin M, Savani BN, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. *Bone Marrow Transplant*. 2015;50(12):1495-1502.
  179. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. *Haematologica*. 2015;100(7):859-869.
  180. Pingali SR, Champlin RE. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. *Bone Marrow Transplant*. 2015;50(9):1157-1167.
  181. Storb R, Sandmaier BM. Nonmyeloablative allogeneic hematopoietic cell transplantation. *Haematologica*. 2016;101(5):521-530.
  182. Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2015;16(15):1525-1536.
  183. Martino R, de Wreede L, Fiocco M, et al; Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT). Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. *Bone Marrow Transplant*. 2013;48(6):761-770.
  184. Passweg JR, Labopin M, Cornelissen J, et al; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2015;50(8):1063-1068.
  185. Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 [abstract]. *Blood*. 2015;126(23). Late Breaking Abstract 8.
  186. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. *Blood*. 2013;122(24):3863-3870.
  187. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen—a report from the acute leukemia working party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 2013;31(28):3549-3556.
  188. Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. *Blood*. 2013;122(24):3871-3878.
  189. Elsayy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2016;51(10):1283-1300.
  190. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2014;32(29):3249-3256.
  191. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. *Blood*. 2014;123(23):3664-3671.
  192. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Lancet*. 1998;352(9134):1087-1092.
  193. Versluis J, Labopin M, Niederwieser D, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. *Leukemia*. 2015;29(1):51-57.
  194. Michelis FV, Messner HA, Atenafu EG, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. *Bone Marrow Transplant*. 2015;50(11):1405-1410.
  195. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. *Blood*. 2011;117(25):6963-6970.
  196. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. *J Clin Oncol*. 2012;30(26):3194-3201.
  197. Bleakley M, Heimfeld S, Loeb KR, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. *J Clin Invest*. 2015;125(7):2677-2689.
  198. Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. *Blood*. 2010;115(16):3224-3230.
  199. de Lima M, Porter DL, Battitalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. *Biol Blood Marrow Transplant*. 2014;20(1):4-13.
  200. Mawad R, Gooley TA, Rajendran JG, et al. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or

- myelodysplastic syndrome. *Biol Blood Marrow Transplant*. 2014;20(9):1363-1368.
201. Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation. *Biol Blood Marrow Transplant*. 2016;22(6):982-990.
202. Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. *Biol Blood Marrow Transplant*. 2015;21(10):1761-1769.
203. Craddock C, Jilani N, Siddique S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial. *Biol Blood Marrow Transplant*. 2016;22(2):385-390.
204. Miller JS. Therapeutic applications: natural killer cells in the clinic. *Hematology Am Soc Hematol Educ Program*. 2013;2013:247-253.
205. Bachanova V, Cooley S, DeFor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. *Blood*. 2014;123(25):3855-3863.
206. Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. *Sci Transl Med*. 2013;5(174):174ra27.
207. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. *Blood*. 2013;122(18):3138-3148.
208. Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. *Leukemia*. 2015;29(8):1637-1647.
209. Lynn RC, Poussin M, Kalota A, et al. Targeting of folate receptor  $\beta$  on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. *Blood*. 2015;125(22):3466-3476.
210. Ossenkuppe G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. *Blood*. 2015;125(5):767-774.
211. Sorror ML, Storer BE, Elsayy M, et al. Impact of comorbidities at diagnosis of acute myeloid leukemia on one-year mortality [abstract]. *Blood*. 2015;126(23). Abstract 532.
212. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*. 2007;109(6):1114-1124.
213. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J Clin Oncol*. 2012;30(21):2670-2677.
214. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*. 2015;126(3):291-299.
215. Döhner H, Seymour JF, Butrym A, et al. Overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts treated with azacitidine by cytogenetic risk status: Results of the AZA-AML-001 study [abstract]. *Blood*. 2014;124(21). Abstract 621.
216. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol*. 2010;28(4):562-569.
217. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. *Leukemia*. 2013;27(9):1803-1812.
218. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. *Blood*. 2015;126(3):319-327.
219. Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. *Leuk Res*. 2011;35(3):301-304.
220. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. *J Clin Oncol*. 2012;30(20):2492-2499.
221. Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. *J Clin Oncol*. 2014;32(18):1919-1926.
222. Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. *Lancet Oncol*. 2015;16(9):1025-1036.
223. Itzykson R, Thépot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. *Leuk Res*. 2015;39(2):124-130.
224. Ivanoff S, Gruson B, Chantepie SP, et al. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. *Am J Hematol*. 2013;88(7):601-605.
225. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. *Leuk Lymphoma*. 2013;54(9):2003-2007.
226. Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukemia in first relapse. *Am J Hematol*. 2013;88(9):758-764.
227. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. *J Clin Oncol*. 2013;31(10):1293-1301.
228. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. *J Clin Oncol*. 2010;28(23):3730-3738.
229. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. *Leukemia*. 2011;25(5):808-813.
230. Jabbour E, Daver N, Champlin R, et al. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. *Am J Hematol*. 2014;89(4):395-398.
231. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. *Blood*. 2006;108(3):1092-1099.
232. Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, et al. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. *Eur J Haematol*. 2016;96(5):475-482.
233. Othus M, Appelbaum FR, Petersdorf SH, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. *Biol Blood Marrow Transplant*. 2015;21(3):559-564.
234. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. *Biol Blood Marrow Transplant*. 2015;21(3):454-459.
235. Ruutu T, de Wreede LC, van Biezen A, et al; European Society for Blood and Marrow Transplantation (EBMT). Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. *Bone Marrow Transplant*. 2015;50(12):1542-1550.
236. Schmid C, Labopin M, Nagler A, et al; EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematologic relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. *J Clin Oncol*. 2007;25(31):4938-4945.
237. Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. *Eur J Haematol*. 2013;91(4):304-314.
238. Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2016;101(7):879-883.
239. Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions—a retrospective multicenter analysis from the German Cooperative Transplant Study Group. *Biol Blood Marrow Transplant*. 2015;21(4):653-660.
240. Davids MS, Kim HT, Bachireddy P, et al; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. *N Engl J Med*. 2016;375(2):143-153.
241. Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. *Best Pract Res Clin Haematol*. 2013;26(4):309-317.
242. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. *Semin Oncol*. 2013;40(6):666-675.
243. Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. *Blood*. 2013;121(15):2996-3004.
244. Hulegårdh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. *Am J Hematol*. 2015;90(3):208-214.



245. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. *J Clin Oncol*. 2001;19(5):1405-1413.
246. Shih AH, Chung SS, Dolezal EK, et al. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. *Haematologica*. 2013;98(6):908-912.
247. Cleven AH, Nardi V, Ok CY, et al. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. *Mod Pathol*. 2015;28(4):552-563.
248. Ok CY, Patel KP, Garcia-Manero G, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. *Leuk Res*. 2015;39(3):348-354.
249. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature*. 2015;518(7540):552-555.
250. Kleiblova P, Shaliti IA, Benada J, et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. *J Cell Biol*. 2013;201(4):511-521.
251. Ruark E, Snape K, Humburg P, et al; Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. *Nature*. 2013;493(7432):406-410.
252. Swisher EM, Harrell MI, Norquist BM, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. *JAMA Oncol*. 2016;2(3):370-372.
253. Zajkovic A, Butkiewicz D, Drosik A, Giglok M, Suwiński R, Rusin M. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. *Br J Cancer*. 2015;112(6):1114-1120.
254. Pharoah PD, Song H, Dicks E, et al; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. *J Natl Cancer Inst*. 2016;108(3):djv347.
255. Schulz E, Valentin A, Ulz P, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. *J Med Genet*. 2012;49(7):422-428.
256. Churpek J, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. *Cancer*. 2016;122(2):304-311.
257. Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. *J Clin Oncol*. 2012;30(19):2300-2302.
258. Kröger N, Brand R, van Biezen A, et al; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT). Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. *Haematologica*. 2009;94(4):542-549.
259. Kayser S, Döhner K, Krauter J, et al; German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. *Blood*. 2011;117(7):2137-2145.
260. Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. *Mediterr J Hematol Infect Dis*. 2011;3(1):e2011032.
261. Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. *Am J Hematol*. 2015;90(5):E80-E85.
262. Estey E, Levine RL, Löwenberg B. Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. *Blood*. 2015;125(16):2461-2466.
263. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. *Nat Med*. 2013;19(6):655.
264. Boonstra PS, Shen J, Taylor JM, et al. A statistical evaluation of dose expansion cohorts in phase I clinical trials. *J Natl Cancer Inst*. 2015;107(3):dju429.
265. Thall PF, Estey EH, Sung HG. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. *Invest New Drugs*. 1999;17(2):155-167.
266. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood*. 2010;116(14):2420-2428.
267. Estey EH, Thall PF. New designs for phase 2 clinical trials. *Blood*. 2003;102(2):442-448.
268. Hills RK, Burnett AK. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. *Blood*. 2011;118(9):2389-2394.
269. Korn EL, Freidlin B. Outcome-adaptive randomization: is it useful? *J Clin Oncol*. 2011;29(6):771-776.
270. Iasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. *J Clin Oncol*. 2014;32(23):2505-2511.
271. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. *Biometrics*. 2008;64(4):1126-1136.
272. Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leukemia: what's the best end point? *Leukemia*. 2016;30(3):521-525.
273. Luskin MR, Lee JW, Fernandez HF, et al. Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: Potential for a surrogate endpoint to facilitate rapid approval of therapies in AML [abstract]. *Blood*. 2014;124(21). Abstract 2599.
274. Othus M, van Putten W, Löwenberg B, et al. Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. *Haematologica*. 2016;101(7):e284-e286.
275. Schlenk RF, Döhner H, Döhner K, et al. Event-free survival is a surrogate for overall survival in patients treated for acute myeloid leukemia [abstract]. *Blood*. 2015;126(23). Abstract 3744.
276. Burnett AK, Hills RK, Hunter AE, et al; UK National Cancer Research Institute AML Working Group. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. *Leukemia*. 2013;27(1):75-81.
277. Burnett AK, Russell NH, Hunter AE, et al; UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. *Blood*. 2013;122(8):1384-1394.
278. Alibhai SM, Leach M, Gupta V, et al. Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. *Crit Rev Oncol Hematol*. 2009;69(2):168-174.
279. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. *Blood*. 2016;127(1):71-78.
280. Grunwald MR, Levis MJ. FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia. *Semin Hematol*. 2015;52(3):193-199.
281. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurinib for patients with FLT3 mutant AML in first relapse. *Blood*. 2011;117(12):3294-3301.
282. Knapper S, Russell N, Gilkes A, et al. A randomised assessment of adding the kinase inhibitor lestaurinib to 1st-line chemotherapy for FLT3-mutated AML [published online ahead of print 21 November 2016]. *Blood*. doi:10.1182/blood-2016-07-730648.
283. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. *J Clin Oncol*. 2013;31(25):3110-3118.
284. Röhlig C, Serve H, Hüttmann A, et al; Study Alliance Leukaemia. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. *Lancet Oncol*. 2015;16(16):1691-1699.
285. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. *Blood*. 2013;121(18):3563-3572.
286. Gallipoli P, Giotropoulos G, Huntly BJ. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. *Ther Adv Hematol*. 2015;6(3):103-119.
287. Issa JP, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. *Lancet Oncol*. 2015;16(9):1099-1110.
288. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science*. 2013;340(6132):622-626.
289. Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial [abstract]. *Blood*. 2015;126(23). Abstract 323.
290. DiNardo C, de Botton S, Pollyea DA, et al. Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study [abstract]. *Blood*. 2015;126(23). Abstract 1306.
291. Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. *Lancet Haematol*. 2016;3(4):e186-e195.
292. Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. *Exp Hematol*. 2015;43(8):673-684.

293. Placke T, Faber K, Nonami A, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. *Blood*. 2014;124(1):13-23.
294. Lichtenegger FS, Krupka C, Köhnke T, Subklewe M. Immunotherapy for acute myeloid leukemia. *Semin Hematol*. 2015; 52(3):207-214.
295. Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. *Leuk Res*. 2014;38(4): 460-468.
296. Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. *Blood*. 2015;126(26):2790-2797.
297. Wandt H, Schaefer-Eckart K, Wendelin K, et al; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. *Lancet*. 2012;380(9850): 1309-1316.
298. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. *N Engl J Med*. 2013;368(19):1771-1780.
299. Gröschel S, Sanders MA, Hoogenboezem R, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. *Blood*. 2015;125(1):133-139.